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Background: Depression is prevalent in older adults, and there is interest in the 
relationship between depression and healthcare utilization among them. However, many 
research findings are inconclusive. 
Objective: This thesis aimed to examine the relationships between psychiatric disorders 
and depressive symptoms, and aspects of healthcare use including hospitalization (Study 
I and Study II), doctor visits (Study II), complementary and alternative medicine (CAM) 
(Study III), and prescription medications (Study IV).   
Methods: The studies were based on data from two population-based research of older 
adults in Singapore: the National Mental Health Survey of the Elderly (NMHS-E), and 
the Singapore Longitudinal Aging Study (SLAS). The participants in NMHS-E was a 
national random sample of 1092 older adults aged 60 and over; and in the SLAS cohort, a 
whole area population of 2804 participants in south east region of Singapore, aged 55 and 
over. In three studies, a cross-sectional design was used, and one was a prospective 
follow up study of a sub-sample (N=973) of SLAS participants. In NMHS-E, psychiatric 
disorders were determined by the Geriatric Mental State (GMS), and in SLAS, depressive 
symptoms were assessed by the Geriatric Depression Scale (GDS). Data obtained from 
questionnaire interview included self-reports of hospitalization, doctor visits, CAM, and 
prescription medications during one year, and socio-demographic data, health status such 
as medical history, functional disability, life-style and behavior. 
Results: Study I: The presence of co-morbid psychiatric disorder was independently 
associated with hospitalization after controlling for number of medical co-morbidities and 
other confounders. Study II did not show a prospective association between depression 
VI 
 
and hospitalization, but baseline depressive symptoms predicted a higher rate of 
subsequent doctor visits during 1 year of follow up. On the other hand, both 
hospitalization and doctor visits during the follow-up were predictive of subsequent 
depression at 1 year. Study III demonstrated that depression and poor self-rated mental 
health were independently associated with CAM use; among depressed respondents, 
CAM users compared to nonusers did not differ in their likelihood to seek professional 
treatment for mental problems, or in their attitudes towards mental illnesses and its 
treatment. Study IV revealed positive associations with depressive symptoms for 
H2-blockers and systemic corticosteroids in participants aged ≥65 , and an inverse 
association with depressive symptoms for statins (HMG-COA reductase inhibitors) use.  
Conclusions: In summary, our results supported that mental disorders and symptoms 
have important relationships with health care use, including prescription medications. 
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CHAPTER 1 INTRODUCTION 
The number of older people in the world is increasing rapidly.
1,2
 During 2000-2030, the 
worldwide population aged >65 years is projected to increase by approximately 550 




Rapid population ageing brings about both social and economic burdens and many urgent 
health-related problems that are needed to be solved. 
 
1.1. The impact of escalation of aging population on healthcare use 
The increase in the number of older people in the population presents a big challenge for 
public health. As more people get older, there will be additional older adults who have 
chronic diseases, disability, and cognitive problems. This will lead to a higher demand of 
health care such as physician visits, hospital admission and medication use, and 
potentially raise health care costs. A previous study reported that health-care cost per 
capita for persons aged >65 years in the United States and other developed countries is 
three to five times greater than the cost for persons aged <65 years .
3
 Moreover, more 
elderly people appeared to have resorted to complementary and alternative medicine 
(CAM) use, with prevalence ranging from 30% to 66% .
4-6 
Due to multiple medication 
use and age-related changes in drug absorption, distribution, metabolism, and elimination, 
drug-related problems such as drug adverse effects and drug-drug interactions are 
common among the elderly population.
7,8
 They have been linked with preventable 
problems in the elderly such as depression, constipation, and falls 
9,10
 ,thus increasing 
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health care expenses. 
 
The increasing use of health care has triggered growing public interest; increasing 
numbers of studies have been directed at identifying the factors that are associated with 
health service use and attempted to find interventions to optimize utilization of the 
limited health resources and improve the general health status of the elderly population. 
 
1.2 Epidemiology of late-life depression and its association with healthcare use 
A potential predictor that is receiving growing research attention is mental disorders and 
symptoms such as depression. Projections suggest that by 2020, depression will become 
the second leading cause of disease burden worldwide, as measured by disability-adjusted 
life years .
11
 Among the elderly, depression is a public health problem. A systematic 
review 
12
 of the world literature reported that the prevalence of depression in late life 
(age>55) ranged from 0.4%-35%. They revealed a weighted average for major depression 
of 1.8% and for minor depression of 9.8%, while all depressive syndromes considered 
clinically relevant reached 13.5%, and a higher rate of prevalence of depression was a 
consistent finding for women and older people in poor socioeconomic status. Another 
study reported that rates of major depression have risen markedly over the past decade for 
the aged population .
13
 Moreover, depression has been shown to be associated with poor 
quality of life,
14
 functional disability ,
15
 cognitive impairment 
16 
as well as cardiovascular 
diseases .
17 
These links between depression and physical illnesses are biologically 
supported, as depressed patients have been found to have a high sympathetic tone, a 
persistently activated hypothalmo- pituitary-adrenal axis, elevated inflammatory markers 
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(particularly cytokines such as tissue necrosis factor-a), endothelial dysfunction and 
abnormally elevated platelet activity .
18-24
 Therefore, whether depression leads to more 
healthcare use has become an important topic of investigation by many researchers. 
 
Rowan and his colleagues 
25
have shown that depression was associated with more doctor 
visits and higher risk of hospitalization in the general population, while Huang et al
26
 
reported that the association between depression and hospitalization was only detected 
among old-old men. A more recent review by Koopmans et al
27
 concluded that mental 
disorders are related to higher general health care service use on a global, aggregated 
level, though these associations are not specific for certain types of services. However, 
the attempts to establish the links between certain types of services and mental disorders 
are still incomplete among community-living older adults. Few studies have investigated 
the relationships between the risk of acute hospitalization and psychiatric morbidities and 
co-morbidities, and studies have not determined whether late-life depression is causally 
related to more doctor visits and hospitalization. This may be explained by factors related 
to study design, study population and the complexity of the relationship between 
depression and measures of health service use in the elderly. Concerning CAM use, some 
studies observed a positive association between depression and CAM use ,
28-30
 while this 
is not confirmed by other research .
31
 Although considerable research on the association 
between depression and CAM use has been devoted to patients in clinical settings, rather 
less attention has been paid to the older population in the community. Few studies 
employ large sample size and depression diagnosis to explore the association of 
depression with CAM use. 
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Additionally, some researchers suggested CAM was used as a complement to 
conventional health care rather than a substitute,
28,32
 and others found CAM use could be 
due to dissatisfaction with conventional care .
33,34
 However, it is not well established 
whether patients with mental disorders use CAM because their needs cannot be met by 
conventional health care. 
     
Depression may cause higher health resource use, while healthcare use can also lead to 
depression. This is exemplified by drug-induced depression. Certain drug classes or drugs 
such as corticosteroids, β-blockers, sedative-hypnotics, and simvastatin have been 
reported to provoke or cause depressive symptoms by early studies either in community 
settings 
35,36
 or in clinical settings .
37-39
 However, a review of evidence from previous 
literature showed that no consensus has been reached on the specific associations 
between the use of most drugs and depression except corticosteroids .
40-42
 As older people 
are at increased risk of drug-related adverse effects, resulting in elevated heath service 
use, it is essential to explore the association between drug use and depression among 
older population. However, population-based research to answer these questions is spotty 
and the findings are inconsistent. Moreover, increasing age alters dramatically the 
pharmacokinetics and pharmacodynamics of drugs, it would be of interest to examine 
whether drug-induced depression changes with age. To our knowledge, this has not been 
explored by early studies. With regard to doctor visits and hospitalization, information on 





1.3 Research Objectives 
The overall aim of the thesis was to investigate the associations between mental disorders 
and symptoms, particularly of depression, and healthcare use in the elderly.  
 
The specific objectives of the studies were: 
1) To investigate the association of psychiatric disorders (depression, dementia etc.) with 
acute hospitalization risk among community-living older adults; (Study I) 
2) To examine prospectively the bi-directional relationship between depression and health 
service use such as hospitalization and doctor visits; (Study II) 
3) To explore the association of depression and self-rated mental health with CAM use, 
and to assess among study participants with depression, whether CAM users differed 
from nonusers in conventional care use and attitude to conventional treatment; (Study III) 
4) To identify specific associations of the usage of different drug classes with the 
presence of depressive symptoms, and to examine whether their associations varied 
between young-old and old-old adults (Study IV) 
 
We used population-based data of community-dwelling elderly and assessed major 
depressive disorder with Geriatric Mental State (GMS)
43
 and depressive symptoms with 
the Geriatric Depression Scale (GDS) .
44
 Data analysis was conducted for cross-sectional 
and longitudinal relationships. The two designs allowed us to examine both concurrent 
and temporal cause-effect relationships between mental disorders and healthcare use.  
 
Our hypothesis was that psychiatric disorders or depressive symptoms were 
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independently associated with more healthcare resource use such as doctor visits and 
hospitalization. The results of our study may shed light on the influence of common 
mental disorders or depressive symptoms on healthcare use. In addition, it could also 
contribute to a better understanding of drug-induced depression. As a result, the research 
could provide valuable information on interventional strategies to reduce healthcare costs 
and improve healthcare quality.  
 
In our study, we investigated several measures of healthcare use: doctor visits, 
hospitalization, conventional drug use and CAM use. The costs of health service use were 
not included in our study. With regard to psychiatric disorders, we focused on major 
depression and depressive symptoms.  
 
In the next chapter, the research literature will be reviewed, and findings of previous 
studies will be discussed for the following: 
1) The association between depression and healthcare use 
2) Factors that determine use of CAM 
3) Drug use and depression  
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CHAPTER 2 LITERATURE REVIEW 
2.1 Depressive symptoms or depression and healthcare use 
In this section, findings of the association between depression and healthcare use are 
reviewed.  
 
It is widely observed that the increase in the number of chronically ill patients in the 
elderly population expands the demand for healthcare use. Various measures of 
healthcare use were used in different studies. They can be classified in 3 categories: 
generic measures, inpatient service use, and outpatient service use. Generic measures 
combine several dimensions of use into one unitary measure such as total health care 
costs, diagnostic test costs, or treatment seeking. Measures of inpatient service use 
include any hospitalization, number of hospitalization episodes, length of stay (LOS), and 
costs of hospitalization. Outpatient service use includes physician visits (general 
practitioner (GP) visits, specialist visits, emergency use) and costs of physician use. The 
findings will be reviewed for both the general population as well as the elderly population, 
and according to study settings: community and clinical settings.  
 
2.1.1 General population 
2.1.1.1 Community sample 
Only a few population-based community studies examined the association of depression 
with inpatient service use, and it is still unclear whether depression is related with 
hospitalization. In a random and representative sample of the Australian population, 
Goldney et al
45
 reported that people with either subsydromal depressive symptoms or 
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major depression were more likely to be admitted into hospital compared with those 
without depressive symptoms, but multiple comorbidity was not controlled for in this 
study. The findings were supported by a prospective study, which reported that depressive 
symptoms measured by Center for Epidemiologic Studies Depression Scale (CES-D) was 
a risk factor of hospitalization and longer hospital stay during the follow-up, independent 
of number of medical conditions .
25
Conversely, another study failed to show any 
association between depressive complaints and subsequent hospital use. 
46 
 
On the other hand, there is evidence that depressive symptoms was positively associated 
with outpatient service use. Studies of cross-sectional design demonstrated that both 
psychiatric disorders 
47
 and depressive symptoms 
45,49
 were associated with more 
physician use. Parallel results were reported in prospective studies. Depressive symptoms 
predicted subsequent doctor visits and higher outpatient charge 
25,46
 during a one-year 
follow-up period. 
 
2.1.1.2 Clinical sample 
In clinical settings, it has been established that depression had a positive relationship with 
generic measures of service use. Some studies have reported that depressive symptoms 
was associated with generic healthcare use .
50,51 
Using data of health care costs, one 
cross-sectional study 
52
 found that depression was positively associated with health care 
cost in the past one year. Similar results were reported by prospective studies among 
primary care patients 
53,54






Much effort has gone into examining the association between depression and inpatient 
service use. Hansen et al 
58
 reported that medical inpatients with depression or anxiety 
were at increased risk of hospitalization during the past 10 years. Moreover, among high 
volume users of medical care, patients with major depression had substantially higher 
rate of hospitalization over the previous 2 years compared with patients with past 
depression or with no history of depression .
59
 The findings were also corroborated by 
prospective studies .
60-63 
In contrast, no association was detected between depressed mood 




Another measure of inpatient service use is readmission after an index hospitalization. It 
has been consistently shown to be predicted by prior depression or depressive symptoms 




The association between depression and LOS in hospital was mainly examined among 
inpatients, and the findings are inconsistent. Levenson et al 
70
 found that patients with a 
high level of psychopathology had a 40% longer median stay than patients with low 
levels of psychopathology. Other studies of inpatients reported that depression was 
significantly associated with longer index hospital stay, 
71-74
 more days of readmission ,
75
 
or longer length of total hospital stay (combination of index admission and follow up 
admission).
60
 In addition, depression was also positively associated with LOS among 
general outpatients 
54
 and high volume users of medical care .
59
 However, other studies 





Outpatient service use has also been extensively studied; empirical evidence supported 
that depression was associated with outpatient service use. In primary care settings, one 
study found that patients with psychiatric comorbidity had a higher likelihood of 
consulting a GP during the past 2 weeks prior to interview compared with those without 
psychiatric comorbidity .
79
 Other research found that depression was independently 
associated with more ambulatory visits in the past 2 years 
59
 and low complexity primary 
care visits over 2 years.
80
 In addition, depression was reported to be prospectively 
associated with specialist visits 
54,81
 and higher outpatient charge 
54
 among patients in 
primary care settings. Concerning other study populations, the association between 
depression and outpatient service use was also identified among inpatients 
82
 and 
outpatients with specific diseases.
52, 56, 60, 83 
 
2.1.2 Older adults 
2.1.2.1 Community sample 
Among the community-living elderly people, the link between depression or depressive 
symptoms and inpatient service use is not well established. Positive findings were 
reported only in subgroups of the older population. An early study by Anttila 
84
 observed 
that depressive symptoms measured by one question was independently associated with 
more frequent subsequent hospitalization in men (OR=1.93) but not in women. Similarly, 
in a 6-month prospective study, Huang et al
26
 reported that people with depressive 
symptoms were 2.4 times more likely to be hospitalized than were non-depressed older 
adults, but only among old-old men, after controlling for self-reported medical conditions, 





found that depressive symptoms was predictive of hospital use among women but not 
men. And also in another cohort study in Copenhagen, Larsen et al 
86
 reported that 
depressive symptoms was marginally related to subsequent hospital use among women 
but not among men, though medical comorbidity was not controlled for in this study. In 




Only a few studies have examined whether depressive symptoms was related to 
outpatient service use in community settings. There was a lack of evidence of a positive 
association. In a small sample (n=88) of old volunteers, depressive symptoms was 
demonstrated to be associated with more physician visits .
91
 However, one study reported 
that neither major depression nor minor depression was associated with GP contacts and 
specialist visits .
87
 The negative associations were confirmed by the same author in a later 
prospective study .
88
 In addition, one cross-sectional study also found that compared to 
those without depressive symptoms, depressed people did not have an excess use of 
doctor or more emergency department visits. 
89 
 
2.1.2.2 Clinical sample 
Data from primary care or hospital inpatient settings have arrived at relatively uniform 
results that depression was associated with total costs of service use. Using data from 
health maintenance organization (HMO) primary care patients, Unützer et al 
92
 reported 
that depressive symptoms measured by CES-D was associated with a significant increase 
in total costs of medical services after adjusting for chronic medical illness, age and sex. 
In another analysis of HMO primary care patients, 
93
 people with Diagnostic and 
 12 
 
Statistical Manual of Mental Disorders IV (DSM-IV) depressive disorders were found to 
be associated with close to 3-fold increased odds of excessive health care costs than those 
without depressive disorders. Comparable findings were also reported in medical or 
surgical inpatients: depressive symptoms was positively associated with medical or 




Inpatient service use was widely examined in clinical samples and the findings varied 
with different measures and characteristics of the study samples. In a large sample of 
male veterans with Parkinson‟s disease, depressive disorders have been found to be 
associated with any hospitalization (OR=1.34) .
95
 Another study of patients with 
end-stage renal disease (ESRD) demonstrated a positive association of depression with 
greater number of hospitalizations.
96
 The findings were supported by studies among 
inpatients, which found that depressed inpatients were at higher risk of readmission 
97,98
 
or had greater number of hospitalizations .
99
 In contrast, neither any hospitalization 
100
 or 
the number of admissions 
101
 was related to depressive symptoms among primary care 
patients.  
 
LOS was commonly examined among inpatients, though few studies examined it in 
primary care settings or patients with specific diseases. Studies have not yet determined 
whether depression is associated with LOS. Among inpatients, cross-sectional studies 
have indicated that depressed older adults were more likely to stay in hospital longer than 
non-depressed counterparts. 
99,102 
Likewise, prospective research among inpatients 





In addition, other prospective studies found that depression was 
significantly associated with longer hospital stay after discharge
103
 or longer length of 
total hospital stay .
105 
However, no significant association was found between depression 
and length of index admission in other studies .
106,107
 As regards other study populations, 
one study of patients with ESRD reported that depression was associated with increased 
hospital days ,
96




Regarding costs of hospitalization, some studies have found that depression was 
associated with increased costs of admission among primary care patients 
93
 or inpatients, 
94,99 
while other studies failed to establish this association in primary care patients .
100,101 
 
Outpatient service use was mainly examined in primary care settings and it has been 
found to be consistently associated with depression or depressive symptoms. In a sample 
of primary care patients aged 65 to 97, depression had a cross-sectional association with 
more doctor visits, 
100
 which was supported by longitudinal studies.
101,108 
The positive 
association between depression and doctor visits was also detected among inpatients, 
patients with specific diseases and institutionalized older adults 
95,98,109 
 In addition, 









2.1.3 Summary: depression and healthcare use 
Both among the general population and among the older population, the findings are 
mixed with regard to the association between depression and healthcare use. The 
inconsistency could be due to differences in the study population, measures of service use, 
methods of assessment of depression, and adjustment of confounders.  
 
In general, depression has been shown to be consistently associated with generic 
measures of service use and outpatient service use, though evidence is less strong for the 
association of depression with inpatient service use. To be specific, among the general 
population, although studies of community samples indicated that depression was a 
predictor of outpatient service use, the findings were more equivocal with regard to 
inpatient service use. However, depression generally increased inpatient service use in 
clinical settings. In addition, studies of clinical samples consistently demonstrated a 
positive association between depression and generic measures of service use and 
outpatient service use. Among the old population, it remains vague whether depression is 
related to inpatient or outpatient service use in community settings. In clinical settings, 
both generic measures of service use and outpatient service use have been shown to be 
predicted by late-life depression, while the findings were less consistent in terms of the 
association between depression and inpatient service use.  
 
As a result, available data are not adequate to address the probable complexity of the 
relationship between depression and health service use among the older population. 




First, when hospitalization was examined among the elderly, only a few prospective 
studies demonstrated a positive association between depression or depressive symptoms 
and hospitalization. However, two of them used either one question or proxy measures to 
determine depression. Moreover, although one other study assessed depression by CES-D, 
medical comorbidity was not controlled for in that study. Therefore, in future prospective 
studies, it is essential that depression should be determined either by validated rating 
scales or clinical diagnosis, and important confounders such as medical comorbidity 
should be adjusted for. 
 
Second, no previous studies have examined whether psychiatric comorbidity influences 
health service use among community-living older population. 
 
Finally, previous prospective studies have mainly focused on one-way relationship 
between depression and health service use, that is, depression or depressive symptoms 
may predict subsequent higher health service use. However, few studies have investigated 
whether higher service use could lead to the presence of depressive symptoms. If so, 
intervention of depression should also be targeted to people with higher service use.  
 
2.2 Prevalence and predictors of CAM use 
The use of alternative medical therapies is prevalent throughout industrialized world over 
the past 20 years. 
110
 The prevalent use of CAM triggers concern about the potential of 
CAM interacting with conventional medications and possible toxicity or other adverse 
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effects caused by CAM. This is particularly important in aging populations, since they 
usually have more chronic illnesses, need more medications, and consequently, are more 
likely to be exposed to adverse effects from drug interaction or toxicity. Therefore, more 
effort has gone into describing the characteristics of the CAM users and identifying the 
possible predictors of CAM use in elderly people to find the reasons for CAM use. 
 
2.2.1 Prevalence of CAM use 
There is a wide divergence in prevalence estimates across studies, depending on the 
nature of the sample studied, the operational definition utilized, and the time periods for 
reporting prevalence.  
   
Population-based surveys in the United States have shown that the prevalence of CAM 
use was high among the general population ranging from 34% to 62% .
111-115 
 One 
Australian population-based study observed a slight increase in the prevalence of CAM 
use from 48.5% in 1993 to 52.1% in 2000 .
116 
A similar increasing trend was observed 
from 1990 to 1999 in the northern Sweden MONICA Project, though the prevalence of 
CAM use was lower, with 30% of the population reporting CAM product use in the 
preceding 2 weeks in 1999 .
117
 A lower prevalence was also reported in a nation-wide 
survey in Italy, about 15.6% of the respondents used at least one unconventional therapy 
during the period 1997- 1999.
118 
 
Although various prevalences of CAM use were reported by different studies, the 
findings consistently demonstrated a high prevalence among the older population. In a 
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study of 728 elderly respondents who were volunteer enrollees in Blue Shield Plan, Astin 
et al
4
 found that about 41% of seniors reported use of CAM in the past 1 year. More 
recently, in a random sample of community-dwelling older population from USA, 
Cheung et al 
119
found that about 63% of the respondents reported use of one or more 
CAM modalities. Studies outside the United States reported a lower prevalence of CAM 
use. For example, one study in Italy found that the prevalence was about 30% among 
community-living older population.
6
 The prevalence of CAM use was also high among 
the elderly of different ethnic groups. Previous research has found that the prevalence of 
CAM use was about 32% among Mexican Americans, 
120
 42% among older Koreans 
121
 




2.2.2 Predictors of CAM use 
In the following section, depression and other factors that have been reported to be 
associated with CAM use will be discussed.  
 
Mental disorders  
As discussed early, depression and other mental disorders are associated with increased 
risk of health service use. However, it remains inconclusive whether depression or other 
psychiatric disorders contributes to CAM use. Mixed findings were reported from 
previous studies. Some studies observed a high rate of CAM use among patients with 
depression or anxiety .
114
 Other studies have suggested high rates of depression or anxiety 
among users of alternative medicine.
113,122-125 
 Davidson et al 
126
investigated the 
prevalence of psychiatric disorders among 83 users of CAM, they found that 69% of 
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them met lifetime criteria of axis I disorder, and 40% met criteria for a current axis I 
disorder, most frequently depressive disorder or anxiety . Data from one national survey 
of non-institutionalized US population have shown that both panic disorder and major 
depression were positively associated with alternative medication use .
28
 A more recent 
study also demonstrated that psychiatric disorders was a predictor of any CAM use 
among the general population.
111 
Likewise, the association between depression or proxy 
measures of depression and CAM use was also indicated among the elderly.
4,6,127
 For 
example, in a community-based sample of 655 older adults, Dello Buono et al 
6 
used 
Brief Symptom Inventory (BSI) to assess depression, and they reported that people with 
depression were more likely to use alternative medicine . However, Pourat et al
121 
reported that older Korean people who used the services of traditional Korean healers had 
fewer depressive symptoms than those who did not use them. Relatively more studies 
focused on patients with cancer to examine the association between depression and CAM 
use. A cohort study of 480 patients with newly diagnosed early-stage breast cancer 
revealed that depression determined by CES-D was associated with new use of 
alternative medicine .
128
 Results of later studies reported similar findings among breast 
cancer patients
129
 and lung transplant recipients .
30
On the other hand, no significant 





Only a few studies examined the effect of anxiety on CAM use. Some observed a positive 
association between anxiety and CAM use, 
29,115






In general populations, most studies reported that younger people were greater users of 
CAM.
28,116 ,132,133  
This differs from other studies, which found no association between 
age and CAM use 
34,111
 or CAM use was more frequent among older people than younger 
people. 
134,135 
The majority of studies of older people failed to detect any association 
between age and CAM use, 
6,120,121,127,136
 but two other studies showed a reverse 
association between age and CAM use 
4,137 
 
It is inconclusive whether gender is related to CAM use. Although some studies 
demonstrated that being female was positively associated with use of CAM, 
117,133,136,137  
 




There is evidence to show that a higher level of education may be associated with higher 
probability of CAM use. The positive association between education and CAM use was 




 and patients 
with specific diseases .
33, 141-143
 However, education was not a significant predictor in 
most of the studies in older populations 
121,144-146
 as contrast with two studies which found 
that CAM users tended to be more educated than nonusers .
4, 136 
 
The association between income and use of CAM is not clear. Only a few studies have 
reported that a higher income level predicted more CAM use ,
139,140,142,143
while other 
studies reported no significant relationship between income and CAM use among the 
general population 
115,132





Race was also examined and found to be related to CAM use. The ethnic variation in the 





 Some studies in USA found that white adults were associated with higher 
CAM use among women or presurgical patients.
139,143
 A study of patients with asthma in 
Singapore observed that Chinese patients were more likely to be users of CAM compared 
to other ethnicities .
148 
 
Although numerous studies have examined the association between marital status and 
CAM, most studies, 
111,121,134,144,146 
either among the general population or the older 
population, did not support their association.  
 
Few studies examined the effect of work status on CAM use, with contradicting results. 
Some results showed that CAM users were more likely to be employed than non-users, 
116,133




Self-reported health status has been reported by several studies to be associated with 
CAM use. In a national population-based study, Astin et al
115
 reported that poor health 
status was predictive of CAM use. Another study of women participants showed that 
women who rated their health as poor were more likely to use CAM .
139
 Moreover, 
gender has been suggested to modify the association between self-reported health and 
CAM use. A Swedish population-based study demonstrated that poorer self-perceived 
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 found that self-reported health status was clearly related to use of dietary 
supplement and natural remedies among men, but the pattern was less pronounced among 
women . On the other hand, some studies did not found any association between 
self-rated health and CAM use 
138,150 
 
Few studies investigated the association of medical comorbidity with CAM use. One 
study conducted among ambulatory gastroenterology patients reported that the presence 
of other medical conditions predicted CAM use,
142
 and other studies found that the 
number of medical conditions was positively associated with CAM use among the 
general population 
28
 and older population.
120 
 
With regard to chronic diseases, arthritis 
121,136 
and chronic obstructive pulmonary disease 
(COPD) 
146
 were found to be related to higher use of CAM, while cardiovascular disease 
and hypertension 
116,117
 have not been reported to be associated with CAM use. 
 
Life style 
The life style factors discussed in this review include current smoking, alcohol 
consumption and physical exercise. Only a few studies explored the effect of life style on 




A recent American survey indicated that adults who were current smokers were less 
likely to use CAM than adults who were former smokers or those who had never 
smoked .
112




Although an Australian survey of the general population found that users of CAM were 
more likely to have a higher alcohol intake than non-users 
133
, another study in older 
patients with arthritis reported that alcohol abstinence was independently associated with 
use of CAM treatments.
146
 In contrast, Astin et al 
4
 found no relationship between alcohol 
consumption and CAM use among the older population. 
 
Regarding physical exercise, some studies reported that people who engaged in physical 
exercise were more likely to be CAM users than those who did not,
4,133,149
 though another 
study did not support the findings .
132 
 
Conventional care use 
Only a few studies have examined the association between conventional care use and 
CAM use. Studies found that frequent doctor visits was positively associated with both 
CAM use 
4,138,146
 and CAM provider visits ,
32
 indicating a complementary role of CAM 
use to conventional medication. However, little research has been done to investigate 
their association among patients with mental disorders. One recent study observed that 
there was no significant difference in conventional health use between respondents with 






Attitude to conventional care 
The association between patients‟ attitude to conventional health care and CAM use has 
only been addressed in a few studies. Some studies found that patients who were 
dissatisfied with their care or doctors were more likely to use CAM.
33,34,130,151
 Conversely, 
other studies reported an inverse association 
28
or no association 
115,142,152
 between attitude 
to conventional care and CAM use. 
 
2.2.3 Summary: predictors of CAM use 
In this section, we reviewed the effects of psychiatric disorders, demographic factors, 
attitude to conventional care, and other factors on CAM use. The studies discussed here 
are characterized by a heterogeneity with respect to study samples (general population, 
old population, patients), the definition of CAM, and the countries of origin. Despite the 
methodological differences, evidence about the associations of possible predictors with 
CAM use can be figured out. 
  
Psychiatric disorders, particularly depression, could be related to CAM use. However, the 
results are contradictory, and moreover, most studies have employed small and selected 
clinical samples of subjects or have used simple self-reports or brief questionnaires for 
mental symptoms, which do not meet diagnostic criteria for common mental disorders. 
The role of depression in CAM use still needs thorough investigation. 
 
Most studies have found that demographic factors play an important role in predicting 
CAM use in the general population. People who used CAM tend to be younger, female, 
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and better educated than those did not use among the general population, but these factors 
have been shown to be less important in predicting CAM use among the older population 
or patients. In general, race and income may have some impact on CAM use, while 
marital status and employment status do not seem to affect CAM use. 
 
Among health status factors, poor self-rated health correlates with CAM use. However, 
whether medical comorbidity is associated with CAM use is less clear and requires 
careful investigation. 
 
No conclusions about the effects of life style factors (current smoking, alcohol 
consumption, physical exercise) on the CAM use can be drawn as the findings are 
conflicting. These associations remain to be examined. 
 
With regard to conventional service use, results of previous studies suggested that CAM 
was used as a complementary or additional therapy to conventional medicine. However, 
information on the relationship between CAM use and conventional medication among 
patients with mental disorders is sparse, and more research is needed to examine whether 
CAM is used by individuals with mental disorders because conventional medical care 
does not meet their needs. Likewise, studies have not determined whether dissatisfaction 
with conventional health care causes increased likelihood of CAM use. 
 
In summary, demographic factors are associated with CAM use. Although depression and 
poor self-rated health have been suggested to increase CAM use among older adults, the 
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association needs to be confirmed by further research. Additionally, future research 
should examine whether patients with mental disorders use CAM because of unmet 
health care needs, and whether attitude to health care affects their CAM use. 
 
2.3 Drug use and depressive symptoms 
 
The prevalence of chronic diseases and drug use increases with age. Because depression 
is common among patients in medical treatment settings, drug-induced depression is of 
considerable clinical and research importance. The knowledge of relevant research 
findings on drug-induced depression is valuable to assist the doctors in making informed 
decision to manage depression. In the following section, we will review previous 
literature that examined the relationship between depression and drugs commonly used in 
the elderly. 
 
2.3.1 Antihypertensives  
 
Reserpine was commonly used in the past and is now replaced due to the availability of 
alternative medications and the drug‟s nervous system adverse effects. Historically, 
reserpine has been reported to provoke or worsen depression in early clinical case 
reports, .
153,154
 The association was likely due to depleting biogenic amines from central 
nervous system neurons by reserpine,
155
 but the scientific validity of these earlier 
observations is questioned .
156,157
 Similarly, depression as a side effect of methyldopa was 
firstly noted in case reports ,
158,159






β-blockers are among the most extensively examined antihypertensives with regard to the 
association with depressive symptoms. Available research findings did not support that 
β-blockers can lead to depression and it is still uncertain whether the association exists. 
162,163
 Initially, numerous case reports have suggested that β-blockers may cause 
depression.
164-167
 Recently, using administrative data, two cross-sectional studies reported 
a positive association between β-blockers and antidepressant use .168,169 In addition, 
another community-based study observed a positive association between β-blockers and 
depressive symptoms measured by CES-D .
35
 However, other cross-sectional studies did 




Findings from prospective studies were conflicting. In a small prospective study of 20 
patients, propranolol was found to have more adverse effects on mood measured by 
Profile of Mood State (POMS) than placebo, these mood effects included depression, 
tension and total mood disturbance .
171
Using antidepressant as a proxy measure of 
depression, another study found that patients under propranolol treatment were 4.8 times 
more likely to use antidepressant than did reference group and 2.1 times more likely than 
did all other drug users.
172
 Also, in a recent large population–based cohort study, 
Sørensen et al
173
 reported that medium and high lipid soluble β-blockers usage may cause 
suicide. In contrast, other studies failed to identify the association between β-blockers and 
clinical depression 
174,175






Similarly, data from case-control studies with regard to the association between 
β-blockers and depressive symptoms are also controversial. Although results from one 
case-control study of diabetic patients have shown that β-blockers was significantly 
associated with high risk of diagnosis of depression ,
176
 other case-control studies did not 
replicate the findings.
177,178
 Regarding randomized clinical trials of β-blockers, some 




   
The evidence supporting an association between calcium channel blockers and depressive 
symptoms was mostly from case reports.
166,181-183
Although some empirical studies have 
identified a positive association between calcium channel blockers and depressive 
symptoms 
35,176
 or antidepressant use,
184
 most of the studies failed to observe the 
relationship with depressive symptoms 
174,178,185
 or suicide .
173,186
 In addition, a recent 
randomized trial has observed a significant improvement in CES-D score after 1-year 
treatment of Verapamil as compared to nonsignficant improvement in the atenolol 
group .
37
 Since randomized clinical trials are still lacking for studies of calcium channel 
blockers, further research of randomized design is warranted to reach more definitive 
conclusions about the potential of calcium channel blockers to cause depression.    
    
Regarding ACE-inhibitors, most of the studies did not find any association between 
ACE-inhibitors and depression 
35,36,176
 or suicide ,
173
 in contrast to two studies: one study 
using „prescription sequence symmetry analysis‟ reported a positive association between 
ACE-inhibitors and antidepressant use,
184
 and another case-control study observed that 
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this connection was stronger in female and respondents aged 65 and over. 
178
 However, 




2.3.2 Lipid-lowering drugs 
 
In the early 1990s, a meta-analysis of 6 randomized clinical trials revealed that 
cholesterol-lowering via diet modification or older pharmacologic agent was apparently 
associated with a significant increase in death from suicide, accidents, and 
violence .
189
This association could be attributable to the lowered serum cholesterol levels, 




 have shown that 
low or lowered serum cholesterol was associated with increased risk of suicide or death 
from suicide. Moreover, based on Beck Depression Inventory (BDI) 
194
 or Zung 
Self-Rating Depression Scale (ZSDS), 
195
 two cross-sectional studies have detected an 
association between low serum cholesterol levels and depressive symptoms in older men. 
In animals, monkeys consuming low-cholesterol diet had increased aggression, and 
decreased social affiliation compared with controls .
196
 It is hypothesized that the link 
between serum cholesterol levels and emotional behavior may be related to serotonergic 
receptor function ,
196.197
 a reduction in serum cholesterol decreases the exposure of 
protein serotonin receptor on the brain-cell-membrane surface, leading to poorer uptake 
of serotonin from the blood and less serotonin into cell.
198
 However, other studies have 
failed to demonstrate the association of low or lowered serum cholesterol concentration 





As a powerful class of lipid-lowering drugs, statins (HMG-COA reductase inhibitors) 
have been introduced in the past decade. Many studies have examined the association 
between statins use and mood disorders. The evidence suggested that statins use may not 
cause mood disturbance. In a randomized clinical trial of patients treated by simvastatin, 
Wardle et al
203
 did not observe significant differences in total and subscale scores of 
mood questionnaire between treated and placebo group. Likewise, other clinical trials 
indicated that neither lovastatin
204
 nor pravastatin 
205
 caused psychological distress or 
depression. A more recent cohort study among community-living old male adults has 
reported that there was no association between statins use and depressive symptoms as 
determined by CES-D, though it suggested that harms of statins use may be present in 
subgroups.
206
 Moreover, some studies demonstrated that long-term statins use may 
improve depressive symptoms. In a nested case-control study, Yang and colleagues 
207
 
reported that current statins use was associated with reduced risk of depression. The 
findings were replicated in another 4-year prospective study among patients with 
underlying coronary artery disease (CAD) .
208
 In addition, other studies have found that 
the inverse association may be present for long-term use, but not for short-term use , of 
statins .
209,210The „antidepressant‟ effect of statins could be mediated by a 
cholesterol-independent immunomodulatory effect or could be due to the improvement of 
tryptophan metabolism arising from statins .
211
On the contrary, only a few research 





The psychiatric effects of corticosteroids have been a long-standing concern. Previous 
research has found that psychiatric effects from corticosteroids included mania, 
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depression and mood disturbance, which usually occurred within the first two weeks of 
corticosteroids therapy, and seemed to be dose related.
213-215
 Shortly after the introduction 
of corticosteroids therapy in the 1940s, numerous small studies and case series reported 
occasional severe mood disturbances such as mania and depression associated with 
corticosteroids.
216-219
 Using both BDI and BSI to assess depression, one small 
cross-sectional study of COPD patients has reported that the group receiving steroids 
treatment had a higher level of depressive symptoms than those who were not receiving 
steroids and had comparable disease severity .
220
 More recently, data from a large 
cross-sectional study (n=73,402) among the general population showed that 1-year 
prevalence of major depression was 3 times as high in corticosteroids treated vs. 
non-treated subjects controlling for age, gender and perceived health .
221
 The association 
was also found by two subsequent cross-sectional studies in community samples, with 
depression determined by Composite International Diagnostic Interview Short Form for 
Major Depression (CIDI-SFMD) 
36
 and CES-D 
35
respectively. In prospective studies, 
there is also evidence indicating that corticosteroids cause depressive symptoms or 
depression. In a study using normal volunteers, Wolkowitz 
222
 reported that after 
challenge with 80mg of oral prednisone for 5 days,75%(9 of 12) of subjects reported 
depression and other mood disturbances. Additionally, the positive association was 




 On the other hand, one case-control 
study in a hospitalized population did not observe the association between corticosteroids 
exposure and depressive disorders, though the possibility cannot be excluded that 






The psychiatric adverse effects of corticosteroids were biologically plausible given the 
overlapping psychological symptomatology between Cushing's disorder and depression 
226
 and observations that changes in the hippocampus structure, secondary to an excess of 
corticosteroids, are central to the development of depression in vulnerable individuals .
227
 
Particularly, the elderly have blunted and delayed inhibition of ACTH secretion in 





The link between H2-blockers use and depression is mostly reported from clinical case 
reports .
229-231
 However, a hospital-based frequency study of intravenous cimetidine 
232
 
and an outpatient cimetidine postmarketing surveillance study
233
 did not find that 
cimetidine caused depression. Data of well-designed empirical studies are rare and the 
results did not support the association between H2-blockers and depression. In a small 
double-blind, randomized clinical trial of ranitidine compared to placebo, depression was 
determined by Hamilton Depression Rating scale for depression (HRSD), an increase of 
depression score was not indicated .
234
 Similarly, using ICD 9 codes to diagnose 
depressive disorders, another case-control study of inpatients did not find that 
H2-blockers use was associated with depression.
235
 So far, only one community-based 
study has examined this association. The cross-sectional study investigated the 
association among older adults and employed CES-D to assess depressive symptoms. 
Although it detected a positive association between H2-blockers and depressive 





 Therefore , substantive evidence is still absent that H2-blockers can induce 
depression. 
 
2.3.5 Other drugs 
 
Some other drugs have also been implicated in causing depression. These drugs include: 
non-steroidal anti-inflammatory drugs (NSAIDs), sedative-hypnotics and diuretics. 
 
Based on a review 
236
 of literature of NSAID-related psychiatric adverse events , Onder et 
al found that reports of NSAID-related psychiatric adverse events have most commonly 
involved indometacin and selective COX-2 inhibitors, and the psychiatric symptoms are a 
rare but relevant complication of NSAID use. This review identified 27 reports with data 
on 453 cases of NSAID-related psychiatric adverse events, no controlled studies are 
available. 
   
It is still uncertain whether sedative-hypnotics can cause depression. Two reviewers have 
concluded that there may be some benefit of concurrent use of antidepressants and 
benzodiazepines.
237,238 
However, in a prospective study of 192 inpatients, Patten et al
38 
reported that sedative-hypnotic exposure was significantly associated with subsequent 
development of depressive symptoms measured by modified CES-D. Similar results were 
also reported in a cross-sectional study in a community-living older population .
35 
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Likewise, the association between diuretics and depression is unclear. Whereas early case 
series
239
 reported that thiazide diuretics prescribed for hypertension induced depression, 
this relationship was not observed in a recent community-based cross-sectional study.
36 
 
2.3.6 Summary of Drug use and depressive symptoms 
In this section, we have discussed several classes of drugs. Among them, lipid-lowering 
drugs and antihypertensives are the most extensively studied drugs. Overall, data are 
insufficient and variant findings have been reported for most of the drugs.  
     
It is highly likely that corticosteroids are causally associated with depression, since the 
association is supported by empirical evidence from well-controlled studies and also 
biologically plausible. Most studies supported that statins use did not lead to depression. 
Conversely, there is no conclusive evidence that antihypertensive use is capable of 
causing depression due to the conflicting findings, and the same is true for other drugs 
including H2-blockers, NSAIDs, sedative-hypnotics and diuretics. 
    
The mixed findings could arise from the lack of well-controlled studies (case-control 
study, cohort study and experimental study), the lack of standardized methods for 
depression assessment and the incomplete control of important confounders. 
 
Although some studies used validated instruments to determine depressive symptoms, 




In observational studies, it is difficult to differentiate psychiatric side effects of drugs 
from the effects of illnesses treated by the drugs, as certain chronic illnesses were also 
related to depression. This problem could be resolved by using experimental studies 
(randomized controlled trail), which can balance the potential confounders well. On the 
other hand, strict eligibility criteria of clinical trials may exclude some subjects leading to 
underestimation of strength of the association between drug use and depression. 
Therefore, in this respect, population-based studies are essential to avoid potential 
selection bias. 
 
So far, very few studies have examined the association between a variety of drugs and 
depression in community settings, and to our knowledge, only one study was conducted 
among community-living older adults.
35
 Moreover, as the elderly have altered 
pharmacokinetics and pharmacodynamics of drugs, they are more vulnerable to drug 
adverse effects than the younger population, it is plausible to speculate that the 
association between drug use and depression could be different in various age strata. 
However, this has not been examined in previous studies. 
 
In sum, more well-designed studies with large sample size and inclusion of validated 
scales for depression assessment should be encouraged to identify the association 
between drug use and depression among the older population. 
   





CHAPTER 3 METHODOLOGY 
 
3.1 Study population 
3.1.1 Study I: Psychiatric disorders and acute hospitalization risk and Study III: 
Depression and self-rated mental health with CAM use 
 
Singapore has a total resident population of 3 million, comprising 77% Chinese, 14% 
Malays and 8% Indians. The proportion of older people aged 65 and over stands at 7.3% 
and this proportion is projected to rise rapidly to 19% by 2030. The analysis in Study I 
and Study III was based on data collected from the National Mental Health Survey of the 
Elderly (NMHS-E), a population-based survey of a nationally representative sample of 
older adults, conducted from 15 February 2003 to 30 March 2004. The respondents were 
a stratified random sample of older adults. The sample was disproportionately stratified 
by ethnicity, so that Malays and Indians were over-sampled in order to enhance the 
statistical precision of ethnic-specific estimates for outcome measures of interest. The 
final effective sample comprised 48% Chinese, 33% Malays, and 19% Indians. 
 
The sampling list of household addresses was generated by the Department of Statistics 
using pure probability sampling from a national sampling frame of dwellings. In each 
household, eligible persons who were older adults aged 60 or above and Singapore 
citizens or permanent residents were identified. Subjects were excluded if they were 
physically or mentally incapacitated to participate. One person per household was 
randomly selected. Selected individuals who refused participation (4.7%) were replaced 
by another eligible subject in another household. A total of 1092 elderly aged 60 and 
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above participated in the survey (72.4% response rate). Respondents gave written 
informed consent for the study which was approved by the Ethics Committee of the 
Institute of Mental Health. 
  
A multi-ethnic and multi-language team of trained field interviewers interviewed the 
respondents at their homes. The majority of them (87%) gave self-reported information; 
where subjects were unable to do so for various reasons, proxy reports were obtained 
from caregivers (13%). Interviews were conducted in English, Mandarin or other Chinese 
dialects and Malay. Indian respondents were interviewed in either English or Malay, as 
they were mostly conversant in either language. 
 
3.1.2 Study II: Depressive symptoms and health service use (hospitalization and doctor 
visits) and Study IV: Drug use and depressive symptoms  
Data of Study II and Study IV were from the Singapore Longitudinal Aging Study 
(SLAS), a prospective cohort study of aging and health of older persons in Singapore. 
The original cohort comprised 2804 older persons who were aged 55 years or older, 
Singaporean citizens or permanent residents, not physically or mentally incapacitated to 
participate in the study, and were recruited through complete door-to-door census for the 
study (response rate 78.5%). Participants signed informed consent for the study which 
was approved by the National University of Singapore Institutional Review Board. 
Baseline assessments were conducted in 2004/2005 from face-to-face interviews. 
Assessments and tests performed by trained research nurses in the on-site study centre 
included extensive range of demographic, biological, clinical, psychosocial and 
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behavioral characteristics. The baseline data of 2804 older adults in 2004/2005 were used 
in Study IV. 
 
Study II, a longitudinal study, used data of 1084 participants who provided baseline 
information for the study at the first wave of re-interview in 2005/2006. The participants 
provided data on depressive symptoms at baseline and at one year, and episodes of new 
doctor visits and hospitalizations at bimonthly intervals through telephone or home 
interviews. Complete data of Study II were provided by 973 participants (90%); 42 
refused to participate, 50 were lost to contact, 10 moved away, and 9 died. The 973 
follow-up participants, compared with the non-participants (n=111), were significantly 
(p<0.05) older, received lower social support, and had poorer functional status, but did 
not differ otherwise on baseline medical comorbidity, depressive symptoms and other 
characteristics. 
 
3.2 Study variables 
3.2.1 Dependent variables 
Hospitalization and doctor visits for non-psychiatric illnesses For every chronic 
illness, respondents were asked to report the frequency of doctor visits and acute 
hospitalization lasting at least 24 hours in the 12-month period prior to the interview 
(Study I) or every 2 months over a follow-up period of 1 year (Study II). 
 
CAM use was determined by an exhaustive checklist that included Chinese herbal 
medicine, Chinese proprietary medicines, Jamu herbal Malay medicines, Ayurvedic 
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medicine, acupuncture, acupressor, moxibustion, reflexology, massage, chiropractic, 
osteopathy, qigong, meditation, yoga, hypnosis/hypnotherapy, aromatherapy, homeopathy, 
spirit medium healing and others. Respondents who reported that they used any one or 
more CAMs in the 12 months prior to interview, either from a practitioner or on their 
own, were classified as CAM users.  
 
Depressive symptoms was assessed by the 15-item GDS short form 
44
 which has been 
validated externally for local use in elderly Singaporeans 
240,241
 The cutoff of 5 or more 
was used to define the presence of depressive symptoms, and has been shown to have 
overall sensitivity of 0.97 and specificity of 0.95 in predicting major depressive disorder, 
with no clinically significant differences in test performance among different age, gender, 
and ethnicity. The overall Cronbach‟s alpha was 0.80; the intraclass coefficient of 
test-retest reliability over two weeks was 0.83; the inter-rater reliability was 0.94.  
 
3.2.2 Independent variables 
Psychiatric disorders (Study I and III) All subjects were administered the GMS 
Schedule, a standardized, semi-structured diagnostic interview instrument, validated for 
use in many studies to assess psychopathology for older adults .
43
 A community version 
of the GMS was derived from the parent schedule which omitted many of the items for 
psychotic disorders unlikely to be encountered in the community, and which has been 
widely used in European community studies .
242
 Diagnoses of organic disorders 
(dementia), depression, anxiety, and other recent psychiatric disorders are made by means 





 using a hierarchical algorithm which corresponds to 
approaches to diagnosis made by a trained psychiatrist. Scores of the symptom 
components from the GMS interview are used to derive scores (0-4 or 0-5) for diagnostic 
clusters, which are then compared according to a hierarchy of diagnoses (organic brain 
syndrome, schizophrenia, mania, depression (major and neurotic), obssessional, 
hypochondriacal, phobic and anxiety neuroses), to provide main and subsidiary diagnoses. 
The GMS has been demonstrated to be able to generate accurate diagnoses of clinical 
dementia, depression and anxiety in elderly people including those with chronic diseases. 
The system provides diagnosis of recent psychiatric disorders by generating five levels of 
diagnostic confidence for determining „caseness‟. A diagnostic confidence level of zero 
denotes absence of a psychiatric disorder; diagnostic confidence levels of 3 to 5 („case‟) 
meet full criteria for DSM-IV diagnoses of dementia, depression, and anxiety, 
schizophrenia and mania; and confidence levels of 1 or 2 (referred to as „sub-case‟) 
denote subthreshold or subsyndromal cases. Subsyndromal depression was considered 
only in study III.  
  
The GMS was translated into Chinese and Malay, and administered by trained psychiatric 
and community nurses and interviewers at the subjects‟ homes. The interviewers 
underwent extensive training in the use of the GMS using training vignettes, completed 
and co-rated four to six supervised training interviews, and received close supervision 
and monitoring of their field interviews. The trainers and supervisors were psychiatrists 




Depressive symptoms (Study II) See above 
Hospitalization and doctor visits See above. 
Drug use All the prescription and non-prescription medications taken by the participants 
in the past year were ascertained from self-reports and physical inspection of pill bottles, 
boxes, packets, diaries and other materials to assist recall. For patients who were unable 
to provide information, the appropriate caregiver most familiar with the patient was 
consulted and provided the information. All the drugs information including drug name, 
indication and duration of use was recorded. 
   
The drugs used were classified by a pharmacist according to the Anatomical 
Therapeutical Chemical Classification of the World Health Organization.
244
 We specified 
10 categories of specific drug classes and one category of other non-specific drugs. The 
10 drug classes were identified from contemporary psychiatric and pharmacological 
reference sources 
40-42
 capable of causing depression for analysis. These included 
antihypertensives (ACE-inhibitors, β-blockers, calcium antagonists), diuretics, 
antiparkinsonism drugs, H2-blockers, statins, NSAIDs, systemic corticosteroids, 
tranquilizers, hypnotic and sedatives.  
 
Social and emotional support was measured with eight questions including respondents‟ 
marital status, living arrangement, frequency of visit or call by children/relative/friends, 
having someone to help when needed or to confide with over personal problems, having 
religious or spiritual support, and financial ability to pay for medical care. Response 
score on each of the questions was converted to z scores and then averaged to yield a 
 41 
 
single, global measure of social emotional support, with high scores indicating higher 
support available. The scores were used to categorize the participants in tertile levels of 
psychosocial support.  
 
Medical comorbidity The presence of major and other specified chronic disorders was 
determined by corroborating information from respondents‟ self-reports of a physician 
diagnosis and treatment in the past 12 months, identification of medications produced by 
the respondents, self-reports of investigative and operative procedures for coronary heart 
and other diseases, and blood pressure, lipids and glucose measurements. The cumulated 
number of chronic illnesses was used to categorize each participant according to the 
number of multiple comorbidity. In NMHS-E (Study I and Study III), the conditions 
included coronary artery disease, heart failure, hypertension, dyslipidaemia, diabetes, 
stroke, cancer, hip fracture, arthritis, asthma, COPD, renal failure, urinary disorders, 
cataract, and other conditions, while coronary artery disease, cancer and urinary disorders 
were left out ,and heart attack and irregular heart beat were added in SLAS (Study II and 
Study IV) . 
 
Cognitive impairment Global cognitive function was measured by Mini-Mental State 
Examination (MMSE).
245
 The Chinese translation of the instrument has been validated 
for local use in Singaporean older adults 
246
 with the conventional cutoff of 23/24 used to 
determine cognitive impairment. Using this cutoff, the MMSE has high sensitivity 




Functional disability was assessed using self-reported measures of Instrumental and 
Basic Activities of Daily Living (IADL and BADL).
247,248
IADL disability was defined as 
needing assistance with 1 or more instrumental activities of daily living. BADL disability 
was defined as being present if the respondents reported difficulty in performing one or 
more basic activities of daily living. 
 
Quality of life was measured using the Medical Outcomes Study 12-item Short Form 
(SF-12).
249
 The 12 items are summarized in two weighted summary scales - Mental 
Component Summary (MCS) score and Physical Component Summary (PCS) score. 
Scores range from 1 to 100, with lower scores indicating poorer health status.  
 
Self-rated health Self-rated physical health (Study II and IV) was assessed by asking the 
participants a single-item question “in general, would you say your health is: excellent, 
very good, good, fair or poor?” We also asked the respondents to rate whether their 
mental health was excellent, very good, good, fair, or poor (Study III).  
 
Health behaviors The respondents were asked whether they regularly visited a health 
care provider for their medical problems (Study I and III), frequency of seeing the same 
family practitioner (Study III and IV), and “To what extent were you limited by financial 
ability to pay for needed health care?” (Study I and Study III ). Information on current 
cigarette smoking and alcohol intake (at least one drink in a week) was also collected 




“Health activities” was measured by the frequency (0=never, 1=sometimes, 3=often) with 
which subjects (1) “watch what you eat”, (2) exercise regularly (2-3 times a week), (3) 
sleep well, (4) have time for leisure . Using similar Likert scale, “physical fitness 
activities” was measured for engaging in “walking”, “exercise routines” and “active 
sports”. “Social activities” was measured for attending religious services, visiting 
cinemas, restaurants, and sports events; day or excursion trips; playing cards, games, 
bingos; participating in social group activities, such as karaoke, line dancing; joining a 
senior citizen club activities . “Productive activities” was measured for hobbies such as 
gardening, painting; preparing meals; shopping; unpaid community work; paid 
community work; other paid employment or business. Each respondent‟s level of health, 
fitness, social and productive activities was measured by their respective summed scores, 
and classified in tertile groups. (Study I and III)   
 
We asked respondents if they sought help from any health professionals either as an 
outpatient or inpatient for emotional or mental health problems in the previous 12 months. 
Included were mental health professionals (MHP) (e.g., psychiatrist, psychologist, and 
other mental health counselors), non-psychiatric and GPs, religious counselors, 
traditional medicine practitioners (e.g., herbalist, acupuncturists), and spiritualists and 
mediums. (Study III)  
 
The respondents’ beliefs and attitudes about doctors and treatment were measured by 
two 5-point (strongly disagree, disagree, neither, agree, strongly agree) Likert scale 
questions: “ Health professionals can do little to help”, “Prescription drugs do more harm 
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than good”. The respondents‟ beliefs and attitudes about mental illnesses and their 
treatment were assessed by questions that asked the extent (not at all, to some extent, to a 
great extent) to which they were embarrassed about mental illnesses, believed mental 
illnesses can be cured, perceived family was able to help, spiritual help was a source of 
support, or were financially limited for needed medical services. Further questions were 
asked for their responses (strongly disagree, disagree, neither, agree, strongly agree) to 
the statements, “Mental health professionals can do little to help”, “Prescription drugs do 
more harm than good”, “I can overcome my problem without professional help”.     
 
Body mass index and lipids Body mass index (BMI) was calculated as weight (in kg) 
divided by the square of height (in m). Respondents with BMI >27.5 kg/m
2 
were 
classified as obese for Asian.
250
 Overnight fasting venous blood samples were tested for 
lipids (TC, TG, HDL, LDL; in mmol/L) using an automatic analyzer (Advia 2400, Bayer 
HealthCare Diagnostics: Coefficient of variation (CV) 1.05 – 2.62% for total cholesterol; 
CV 1.36% – 4.32% for Triglyceride, CV1.4% – 5.97% for HDL) by the dry chemistry 
method. Participants‟ total cholesterol values were categorized into quartile groups.  
 
Other independent variables included gender, age, ethnicity (self-designated by the 
respondents), marital status ,education, employment status, household income, housing 
type (as a surrogate of socio-economic and income status), living arrangement, extent of 
financial inability to pay for needed health care, extent of family help and support, type 




3.3 Data analysis 
3.3.1 Study I: Psychiatric morbidity and acute hospitalization risk 
We used logistic regression analysis to calculate odds ratios (ORs) of association with 
95% confidence intervals (CI) of psychiatric morbidity with hospitalization, which were 
adjusted in a full multivariate model for potential confounding by age, gender, ethnicity, 
housing type, living arrangement, number of medical co-morbidities, psychiatric 
disorders, number of ADL limitations, hearing and visual impairment, SF-12 PCS, SF-12 
MCS, social, productive, fitness and health activities ,and regular visit to healthcare 
provider . Given the disproportionate stratified sampling, weighted analyses were 
performed to provide estimates re-weighted to the actual ethnic distribution in the general 
population using SAS software (SAS Institute, Inc., Cary, NC). 
 
3.3.2 Study II: Depressive symptoms and health service use (hospitalization and doctor 
visits) 
Baseline characteristics of the depressed (GDS score≥5) and non-depressed respondents 
were compared using t-tests for continuous variables and 2 tests for categorical 
variables. The Wilcoxon rank-sum test was used for comparison of doctor visits. 
 
The risk of hospitalization associated with baseline depressive symptoms was estimated 
via bivariate and multivariate Cox proportional hazards regression analysis, using time to 
first hospitalization as the dependent variable. The proportional hazard assumption was 
met in all the models. The association between baseline depression and subsequent doctor 
visits was estimated by unadjusted and adjusted ORs from Poisson regression analyses. 
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Given the highly skewed and overdispersed nature of doctor visit counts, scale parameter 
was adjusted by Pearson's chi-square statistic. The natural logarithm of time at risk was 
used as an offset variable in the regression model to adjust for the effect of varying times 
at risk. Covariates adjusted for in the multiple regression models included age, gender, 
education, ethnicity, housing type, social-emotional support, medical comorbidity, 
self-rated physical health, ADL and IADL disability and cognitive impairment. 
 
The reverse associations between hospitalization and doctor visit measures of health 
service use during the study period and subsequent depression at 1 year were modeled 
using logistic regression. The frequency of doctor visits was divided into 2 categories 
using 5 doctor visits as cutoff point. Besides the above-mentioned covariates, the 
analyses also controlled for confounding by baseline levels of depression by both 
modeling it as a baseline covariate and by excluding participants with depressive 
symptoms at baseline.  
 
 
We also explored possible interactions between depression and other covariates in the 
regression models. A two sided P-value of <0.05 was considered as statistically 
significant. All analyses were performed using SAS software (SAS Institute, Inc., Cary, 
NC). 
 
3.3.3 Study III: Depression and self-rated mental health with CAM use 
All the respondents to the study were categorized as CAM users or non-users. The 
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relationships between respondents‟ characteristics and CAM use were first analyzed 
using univariate logistic regression. Variables that were significant (P<0.10) at univariate 
level were introduced into multivariate logistic regression analysis, with 
multi-collinearity checks; adjusted ORs of association were estimated, adjusting for 
potential confounders. Factors in multivariate logistic models were removed in stepwise 
fashion, and model building was stopped when all factors remained significant in the 
model and no other extraneous variables added significantly to the model at the 0.05 level. 
Significant factors in the final model included presence of psychiatric disorders , 
self-rated mental health, age, ethnicity, regularly visiting to a health care provider, seeing 
the same GP, social activities score and attitude to prescription drugs. Next, a subgroup 
analysis was performed among respondents with depression. The variables of interest 
were compared between CAM users and non-users by 2 test, and a two sided P-value of 
<0.05 was considered as statistically significant. 
 
The analysis took into account the disproportionate sampling by ethnicity, and used 
sampling weights for the general population to generate population-weighted prevalence 
estimates, weighted analyses for logistic regression were performed using SAS software 
(SAS Institute, Inc., Cary, NC). 
 
3.3.4 Study IV: Drug use and depressive symptoms 
Bivariate associations of depressive symptoms with participants‟ characteristics and 
medications use were assessed by t-tests for continuous variables and 2 tests for 
categorical variables. All variables of drug use and those of participants‟ characteristics 
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found with p≤0.20 in bivariate analyses were entered as candidate variables into 
multivariate logistic regression. In addition to those of drug use, the candidate variables 
included age, educational status, housing type, social-emotional support, number of 
medical conditions, functional disability, cognitive impairment, self-rated physical health 
and type of medical facility. When examining the association between statins use and 
depressive symptoms, additional adjustments for BMI and cholesterol level were 
performed to examine their mediating effect. Relative risks were estimated by ORs and 
their 95% CI. The interactions between age (cutpoint 65 years) and each medication use 
were also explored in the multivariate model: we constructed all the interaction terms 
first and then used both purposeful selection and stepwise selection methods to choose 
significant interaction terms from the main effect model.
251
 Both selection methods 
yielded the same results. Subgroup analyses were performed for variables with significant 
interaction (p<0.05). In the subgroup analysis, ORs were also adjusted for age in 5 years 





4.1 Study I: Psychiatric disorders and acute hospitalization risk  
In this population sample of 1092 persons aged 60 years and older, 136 (12.5%) were 
hospitalized at least once during the 12-month period prior to interview. The mean age of 
the respondents was 69.4 ± SD 7.1; 23% were aged ≥ 75 years (Table 1); 16.6% remained 
actively employed. About one half (53%) of the respondents had at least 2 medical 
conditions in the past one year (Table 1). Nearly 13.5% (N=147) of the subjects had one 
or more case level diagnoses of psychiatric disorders in the past one year: 6.5% (N=71) 
had dementia only, 3.7% (N=41) had depression only, and 3.2% (N=35) had co-morbid 
psychiatric disorders (dementia, depression, anxiety). About 17% had limitations in at 
least one ADL. Most respondents (60%) visited a health care provider regularly in the 
past one year. Respondents with psychiatric disorders were significantly less likely to be 
in active employment, had significantly more medical co-morbidities, more ADL 
limitations and poorer physical health status reports, and more frequently visited their 
regular physicians.  
 
In univariate analysis (Table2), psychiatric disorders (OR, 2.19; 95% CI, 1.33-3.59), and 
in particular co-morbid psychiatric disorders (depression, dementia, anxiety and other 
disorders), (OR, 4.10; 95% CI 2.03-8.26), was significantly associated with 
hospitalization. In multivariate analysis, co-morbid psychiatric disorders was 
independently associated with hospitalization (adjusted OR, 2.48; 95% CI, 1.07-5.72), 
after controlling for age, gender, ethnicity, housing type, living arrangement, employment 
status, number of medical co-morbidities, number of ADL limitations, hearing and visual  
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Table 1. Descriptive characteristics of subjects, Singapore National Mental Health Survey, 2003 (N=1092) 























         
Female gender 597 (54.7) 494 (52.3) 57 (80.3) 25 (61.0) 21 (60.0) 2 =18.70 3 0.0003 
         
Age ≥75 250 (22.9) 193 (20.4) 38 (53.5) 10 (24.4) 9 (25.7) 2=47.61 3 <0.0001 
         
Ethnicity: Chinese 501 (45.9) 450 (47.6) 19 (26.8) 12 (29.3) 20 (57.1) 2=15.57 6 0.0163 
         Malay 354 (32.4) 297 (31.4) 34 (47.9) 15 (36.6) 8 (22.9)    
         Indian 237 (21.7) 198 (21.0) 18 (25.4) 14 (34.2) 7 (20.0)    
         
Housing type         
   1-2 room 100(9.2) 84(8.9) 2(2.8) 11(26.8) 3(8.6) 2=21.61 3 <0.0001 
   3-4 room  785(71.9) 681(72.1) 48(67.6) 25(61.0) 31(88.6)    
   5-room and above  207(18.9) 180(19.0) 21(29.6) 5(12.2) 1(2.9)    
         
Living alone 56(5.1) 52(5.5) 1(1.4) 2(4.9) 1(2.9) 2=3.05 3 0.3837 
 1036(94.9) 893(94.5) 70(98.6) 39(95.1) 36(97.1)    
Number of medical conditions         
    0 or 1 517 (47.3) 469 (49.6) 24 (33.8) 12 (29.3) 12 (34.3) 2=19.17 3 0.0003 
    ≥2  575 (52.6) 476 (50.4) 47 (66.2) 29 (70.7) 23 (65.7)    
         
Number of ADL Disabilities         
   0 907 (83.0) 819 (86.7) 40 (56.3) 29 (70.7) 19 (54.3) 2=73.35 3 <0.0001 
   1-2 123 (11.3) 94 (10.0) 16 (22.5) 6 (14.6) 7 (20.0)    
   >=3 62 (5.7) 32 (3.4) 15 (21.1) 6 (14.6) 9 (25.7)    
         
SF-12 health status index         
PCS score (range: 1-100) 47.2±8.86 51.0±9.26 42.5±12.80 46.4±11.49 43.5±11.58 2=26.77 3 <0.0001 
MCS score (range: 1-100) 53.0±7.37 51.2±9.05 47.2±10.91 39.5±12.45 36.8±11.96 2=37.90 3 <0.0001 
         
MMSE 23 (cognitive 
impairment) 
326 (29.8) 226(23.9) 69(97.2) 18(43.9) 13(37.1) 
2=167.19 3 <0.0001 
         
Hearing impairment 91 (8.3) 67(7.1) 14(19.7) 6(14.6) 4(11.4) 2=11.17 3 0.0108 
         
Visual impairment 131 (12.0) 97(10.3) 17(23.9) 12(29.3) 5(14.3) 2=19.33 3 0.0002 
         
Visit a health care provider 
regularly 
657 (60.2) 550(58.2) 46(64.8) 33(80.5) 28(80.0) 
2=11.54 3 0.0092 
         
Social activities score, mean ± 
SD 
2.81±1.90 2.96±1.88 1.54±1.65 2.02±1.70 2.46±2.06 
F=13.01 3 <0.0001 
         
Health activities score, mean ± 
SD 
9.44±1.96 9.54±1.94 8.59±2.07 8.95±1.88 8.83±2.26 
F=6.20 3 <0.0001 
         
Fitness activities score, mean ± 
SD 
2.4±1.37 2.49±1.37 1.73±1.22 2.07±1.15 1.91±1.46 
F=10.72 3 <0.0001 
         
Productive activities score, mean 
± SD 
3.37±1.95 3.52±1.90 2.25±1.99 2.73±1.99 2.46±2.11 
F=16.40 3 <0.0001 
         
Hospitalization(s) in past year 136 (12.5) 109(11.5) 8 (11.3) 8 (19.5) 11 (31.4) 2=19.29 3 0.0002 
         
p values of global tests of significance using analysis of variance for continuous data and chi-squared test for 
categorical data. 





impairment , SF-12 PCS, SF-12 MCS, social, productive, fitness and health activities, 
and regular visits to a healthcare provider.  
 
Other significant variables associated with hospitalization in multivariate analyses included 
number of medical conditions (p<0.001), self-rated health status (p<0.001), and regular 
visits to primary healthcare provider (p<0.03). Respondents who had two or more medical 
conditions were at significantly greater risk of hospitalization (adjusted OR, 2.9; 95% CI, 
1.7-5.1). Better self-rated physical health status was significantly associated with lower 
risks of hospitalization, as shown for SF-12 PCS score in the middle tertile (adjusted OR, 
0.34; 95% CI, 0.19-0.59) and the highest tertile (adjusted OR,0.32; 95% CI, 0.18-0.60) 
versus the lowest PCS tertile. Regularly visiting a primary healthcare provider was 

























Table 2. Odds ratio of association of significant variables with acute hospitalization for 
non-psychiatric illnesses (N=1092) 
 
                   
Univariate analysis  Multivariate analysis * 
OR 95% C.I. P value  OR 95% C.I. P value 
        
Presence of psychiatric  
disorder (ref: None) 
       
   Dementia only 1.15 0.47-2.81 0.75  0.58 0.20-1.62 0.29 
   Depression only 2.02 0.79-5.12 0.14  0.93 0.33-2.65 0.89 
   Co-morbid psychiatric 
disorder  
4.10 2.03-8.26 0.001  2.48 1.07-5.72 0.033 
        
 
Adjusted in model including age, gender, ethnicity, housing type, living arrangement, number of medical 
co-morbidities, number of ADL limitations, hearing and visual impairment, SF-12 PCS, SF-12 MCS, social, 
productive, fitness and health activities, regular visit to healthcare provider   
 
Model fit statistics: 
-2 log likelihood of final model = 629.69 (2 = 116.29; dF=28; p< .0001) 
Pseudo R
2 
= 0.10 (Cox and Snell) and 0.20 (Nagelkerke);% of predicted vs. observed = 75 (percent 
concordant); 





4.2 Study II: Depressive symptoms and health service use (hospitalization and doctor 
visits 
Among the 973 respondents, 48 (4.9%) were depressed at baseline and 31 (3.2%) were 
depressed at 1 year (Table3). At baseline, depressed respondents were older, reported lower 
psychosocial support and had higher baseline GDS score compared to the non-depressed 
respondents. A significantly higher proportion of depressed respondents had 3 or more 
chronic medical conditions, ADL disability, IADL disability, cognitive impairment, and 
classified their health as poor or very poor than did non-depressed respondents. Other 





Table 3 also shows the association between baseline depressive symptoms and health 
service use measures of hospitalization and doctor visits. Because no interaction term was 
significant in this model, we did not consider interaction in the final model. In both 
bivariate and multivariate analysis using Cox proportional hazards regression, baseline 
depressive symptoms was not associated with increased risk of hospitalization. On the other 
hand, baseline depressive symptoms was significantly associated with more doctor visits in 
bivariate Poisson regression , and this association remained significant after adjusting for 
medical comorbidity, self-rated health, functional status and other covariates (adjusted 
RR,1.34; 95% CI, 1.05-1.70).  
 
The results of analyzing the reverse association between hospitalization and doctor visits 
measures of health service use during the one year study period and subsequent depressive 
symptoms at 1 year are summarized in Table 4. Participants who were hospitalized during 
the study period were more likely to report depressive symptoms at 1 year (adjusted OR, 
6.43, 95% CI, 2.48-16.6). Likewise, compared with those with less than 5 doctor visits 
during the study period, participants who reported 5 or more doctor visits were more likely 
to report depressive symptoms at 1 year (adjusted OR,5.89, 95% CI, 2.26-15.36). 
 
To account for the presence of depressive symptoms at baseline, the analyses were repeated 
by restricting subjects to those without depressive symptoms at baseline; similar 
associations with incident cases of depressive symptoms at one year were observed for both 
hospitalization and doctor visits. 
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N %  N %  
GDS at baseline, mean (SD) 0.76 (1.05)  7.70 (2.39)  <0.0001 
Depressed at one year        
  Yes  22 2.4  9 18.8  <0.0001 
  No 903 97.6  39 81.3   
Age       0.07 
 55-65 333 36.0  14 29.2   
 65-75 427 46.2  19 40.0   
 ≥75 165 17.8  15 31.3   
Gender(male) 336 36.4  14 29.2  0.311 
Ethnicity (Chinese) 876 94.7  44 91.7  0.325 
Education        0.099 
No education 197 21.3  13 27.1  0.34 
Educated 728 78.7  35 72.9   
Housing type       0.189 
1-3 rooms public housing  277 30.0  16 33.3   
4-5 rooms public housing 424 45.9  16 33.3   
Other higher end housing 223 24.1  16 33.3   
Psycho-social support        0.0002 
Low (≤49) 252 27.3  26 54.2   
Intermediate(49-53) 325 35.2  14 29.2   
High (>53) 347 37.6  8 16.7   
Comorbidities:  0 270 29.2  12 25.0  0.045 
              1  247 26.7  7 14.6   
2 190 20.5  11 22.9   
             ≥3   218 23.6  18 37.5   
BADL disability 45 4.9  13 27.1  0.0001 
IADL diability 144 15.7  25 52.1  0.0001 
Cognitive impairment 83 9.2  10 22.7  0.008 
Self-rated physical health       0.0001 
  poor or very poor 192 20.8  25 52.1   
Fair, Good or excellent 733 79.2  23 47.9   
        
Hospitalization during follow-up 68 7.4  6 12.5  0.25 
Doctor visits during follow-up, mean (SD)  5.1 (5.1)  8.5 (7.2)  0.0001 
                         median (range)        4.0 (0-65)  7.0 (0-41)   
Adjusted relative risk (95% C.I.)        
  Hospitalization during follow-up§ 1.00   1.06 (0.44-2.58)  0.90 
  Doctor visits during follow-up¶ 1.00   1.34 (1.05-1.70)  0.021 
        
* Adjusted for age, gender, education, ethnicity, housing type, social-emotional support, medical comorbidities, self-rated 
physical health, ADL and IADL disability, cognitive impairment. 
§ Hazard ratio from Cox regression  









 Depression at 1 year follow up  
 N % P  Adjusted OR (95% C.I.) P 
           
Among depressed and non-depressed participants at baselinea           
           
    No hospitalizations in the year  899 21 2.34   1    
    At least one hospitalization in the year  74 10 13.51 0.0001  6.43 (2.48-16.65) 0.0001 
           
Among non-depressed participants at baselineb           
    No hospitalizations in the year  857 14 1.63   1    
    At least one hospitalization in the year  68 8 11.76 <0.0001  10.22 (3.36-31.06) 0.0001 
           
           
Among depressed and non-depressed participants at baselinea           
    ≤5 doctor visits  623 8 1.28 0.0001  1    
    >5 doctor visits  350 23 6.6   5.89 (2.26-15.36) 0.0003 
           
Among non-depressed participants at baselineb           
    ≤5 doctor visits  605 5 0.83 0.0001  1    
    >5 doctor visits  320 17 5.31   7.37 (2.23-24.41) 0.0011 
           
 
a:Adjusted for baseline depression, age, gender, education, ethnicity, housing type, social-emotional support, medical comorbidities, 
self-rated physical health, ADL and IADL disability, cognitive impairment. 
b: Adjusted for age, gender, education, ethnicity, housing type, social-emotional support, medical comorbidities, self-rated physical 




4.3 Study III: Depression and self-rated mental health with CAM use 
In the sample, the mean age was 69.4 (SD=7.1, range of 60 to 94 years); 56.3% were 
female, 80% were Chinese and close to 20% had a house hold income below $1000 
(Table 5). Respondents who met diagnostic criteria which define specific psychiatric 
disorders totaled 226 (19%). Among them, 3.4% (N=50) had dementia only, 10% (N=120) 
had depression (syndromal and subsyndromal) only, and 5.1% (N=56) had depression 
co-morbid with anxiety, dementia and other disorders. Nearly 8% reported their mental 
health as poor or fair, and close to one third had more than two medical conditions. Close 
to 10% indicated they distrusted prescribed Western medicine, and 5% never visited 
regularly the same family practitioner. 
 
Overall, an estimated 44.6% of the population reported having used any CAM in the past 
12 months. Chinese herbal medicine was the most common CAM used by an estimated 
30.6% of the respondents, followed by Chinese proprietary medicines (7.2%); other 
CAMs were far less commonly reported (Table 6). The population estimate of CAM 
users among those who met diagnostic criteria for any mental disorder was 53%, and was 
higher (60%) among those with depression (both syndromal and sub-syndromal). 
 
As shown in Table 7, compared to nonusers, CAM users were more likely to include a 
higher proportion of those who reported their mental health as „poor or fair‟ (p=0.0046), 
and a higher proportion who met criteria defining mental disorder (p=0.006), and 
depression (cases and subcases included, p=0.0004). Also, CAM users were more likely 
to visit a health care provider regularly and to have positive attitude to prescription drugs 
than non-users. Multivariate analyses (Table 8) revealed that self-rating of „poor or fair‟ 
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mental health was significantly associated with CAM use (OR, 2.40; 95% C.I., 1.23-4.71) 
independent of other potential predictors of CAM use. In the presence of self-reported 
mental health status and other confounding risk factors, depression (include sub-cases) 
was also independently associated with CAM use (OR, 2.06; 95% C.I., 1.31-3.25).  
 
Other variables that were significantly associated with CAM use in multivariate analyses 
included older age (≥80), Chinese ethnicity, greater participation in social activities. 
CAM use was significantly associated with regularly visiting a healthcare provider, 
seeing the same practitioner only “some of the time or almost never”, and “strongly 
disagree or disagree” that “Prescription drugs do more harm than good”. 
 
Among 131 respondents with syndromal and subsyndromal depression, Chinese herbal 
medicine was most frequently used (22.1%), the next was Chinese proprietary medicines 
(9.9%), and the others were rarely used. we observed that only 16 respondents reported 
seeking treatment from GPs or MHPs (14%). (Table 9)  We compared CAM users and 
nonusers and found little difference between them in health beliefs, attitudes and 
behaviors. The results did not show that CAM users were less likely to seek treatment 
from conventional Western health professionals or that they were more likely to have 
negative beliefs and attitudes about mental illnesses and treatment by conventional 
healthcare providers. Indeed, CAM users appeared less likely to be embarrassed about 







Table 5. Sample respondents’ characteristics and population-weighted proportions (N=1092) 
Variable N Population-weighted % 
      
Age    
  60~69 629 55.9 
  70~79 347 31.9 
  80~ 116 12.2 
   
Female gender 597 56.3 
   
Ethnicity    
   Indian 237 9.0 
   Chinese   501 80.0 
   Malay 354 11.0 
   
Income   
   <$1000 242 19.6 
   $1000~$2999 633 57.7 
   ≥$3000 217 22.7 
   
Chronic medical conditions   
   None 239 20.5 
   1~2 conditions 498 47.3 
   >2 conditions 355 32.2 
   
Visit a health care provider regularly 657 60.0 
   
See the same GP   
    Most of the time /always 910 85.1 
    Some of the time 110 9.4 
    Almost never 70 5.5 
   
Prescription drugs do more harm than good   
   No (Strongly disagree/disagree) 730 68.1 
   Neutral (Neither agree nor disagree) 255 22.3 
   Yes (Agree/strongly agree) 107 9.5 
   
Physical activity levels   
   Low (0) 300 26.1 
   Intermediate (1~2) 518 46.0 
   High  (≥3) 274 27.9 
   
Social activity levels   
   Low (0~2) 512 42.2 
   Intermediate (3~5) 487 47.0 
   High (≥6) 93 10.8 
   
Productive activities   
   Low (≤2) 364 28.7 
   Intermediate (3~5) 570 55.9 
   High (≥6) 157 15.4 
   
Presence of psychiatric disorder   
   None 866 81.5 
   Dementia only 50 3.4 
   Depression only (case level)  41 2.9 
   Depression only (include subsyndromal cases) 120 10.0 
   Depression co-morbid with other disorders 56 5.1 
   Any psychiatric disorders 226 18.5 
   
Self-rated mental health   
   Excellent 116 11.0 
   Good/very good 860 81.3 
   Poor / Fair 116 7.8 
   
CAM use 401 44.6 
   Except for ethnicity, figures show percentages that were weighted using sampling weights for the general population 
to adjust for disproportionate sampling of respondents by ethnicity 





Table 6.  Frequency of use of complementary and alternative medicines (CAMs) 
 
Therapy  Unweighted Sample N Weighted population % 
Any CAM 401 44.6 
Chinese herbal medicines 202 30.6 
Chinese proprietary medicines 52 7.18 
Massage 68 4.42 
Others  46 4.17 
Qigong 25 3.99 
Acupuncture 24 3.71 
Reflexology 35 3.58 
Meditation 28 2.52 
Jamu herbal Malay medicines 55 1.74 
Ayurvedic medicine 11 0.53 
Acupressor 4 0.51 
Yoga 9 0.34 
Aromatherapy 4 0.26 
Spirit medium healing 2 0.20 
Moxibustion 1 0.16 
Chiropractic 1 0.04 
Osteopathy 0 0.00 
Hypnosis/hypnotherapy 0 0.00 
Homoepathy 0 0.00 
   
 
Percentages are weighted using sampling weights for the general population to adjust for 





























Table 7. Univariate analysis: Significant variables (p<0.10) associated with CAM use in older adults aged≥60 years 
Variables Users (N=401) Non-Users (N=691) OR* 95% C.I. P value 
 N Weighted % N Weighted %    
        
Presence of psychiatric disorder       0.0029 
   None 313 77.8 553 84.4 1.00   
   Dementia only 15 3.1 35 3.7 0.91 0.47-1.77 0.78 
   Depression only (case level)  16 3.7 25 2.3 1.81 0.88-3.69 0.11 
   Depression only (include subsyndromal cases) 54 13.7 66 7.1 2.09 1.39-3.14 0.0004 
   Depression co-morbid with other disorders 19 5.4 37 4.8 1.22 0.71-2.11 0.47 
   Any psychiatric disorders 88 22.2 138 15.6 1.54 1.14-2.10 0.006 
        
Self-rated mental health       0.0046 
   Excellent 49 5.1 66 9.9 1.00   
   Good/very good 316 82.1 545 80.6 1.96 1.20-3.18  
   Poor / Fair 35 12.8 81 9.5 2.58 1.43-4.65  
        
Age        0.0005 
  60~69 229 54.1 400 57.4 1.00   
  70~79 118 29.5 229 33.9 0.92 0.71-1.20  
  80~ 54 16.5 62 8.8 1.99 1.36-2.92  
        
Female gender 229 60.2 368 53.1 1.34 1.05-1.70 0.019 
        
Ethnicity        0.0001 
   Indian 52 4.4 185 12.7 1.00   
   Chinese   247 88.5 254 73.2 3.46 2.11-5.68  
   Malay 102 7.1 252 14.1 1.44 0.78-2.68  
        
Income       0.012 
   <$1000 75( 16.6 167 22.0 1.00   
   $1000~$2999 227 57.2 406 58.1 1.30 0.95-1.79  
   ≥$3000 99 26.2 118 19.9 1.75 1.20-2.53  
        
Chronic medical conditions       0.018 
   None 78 16.8 161 23.6 1.00   
   1~2 conditions 194 50.5 304 44.7 1.58 1.15-2.19 0.005 
   >2 conditions 129 32.7 226 31.7 1.45 1.03-2.04 0.035 
        
Visit a health care provider regularly 256 65.5 401 55.5 1.52 1.19-1.94 0.0009 
        
See the same GP       0.038 
    Most of the time /always 320 82.3 590 87.4 1.00   
    Some of the time 48 11.9 62 7.4 1.69 1.12-2.56 0.012 
    Almost never 32( 5.8 38 5.2 1.18 0.70-2.00 0.53 
        
Prescription drugs do more harm than good       0.0001 
   No (Strongly disagree/disagree) 294 74.8 436 62.8 1.90 1.40-2.56  
   Neutral (Neither agree nor disagree) 70 16.8 185 26.8 1.00   
   Yes (Agree/strongly agree) 37 8.4 70 10.4 1.29 0.81-2.08  
        
Physical activity levels       0.037 
   Low (0) 87 22.3 213 29.2 1.00   
   Intermediate (1~2) 199 48.3 319 44.1 1.43 1.07-1.93 0.018 
   High  (≥3) 115 29.3 159 26.8 1.43 1.03-1.99 0.032 
        
Social activity levels       0.0001 
   Low (0~2) 149 33.8 363 49.0 1.00   
   Intermediate (3~5) 205 52.5 282 42.5 1.79 1.38-2.32  
   High (≥6) 47 13.7 46 8.5 2.34 1.55-3.52  
        
Productive activities       0.009 
   Low (≤2) 106 24.9 258 31.8 1.00   
   Intermediate (3~5) 218 56.9 352 55.1 1.32 1.00-1.74 0.051 
   High (≥6) 76 18.2 81 13.1 1.78 1.22-2.60 0.0029 
          * Weighted estimates of odds ratios and 95% confidence intervals  
Non-significant (p>0.10) variables are not shown in the Table: educational level, marital status, employment status, reported extent of financial ability to pay for needed 
healthcare, extent of family help and support, health insurance (yes,.no), self-rated physical health status (poor/fair, good, very good/excellent), functional status  
(non-dependence, IADL dependence only, IADL and/or ADL dependence), cognitive impairment (MMSE <23), distrust of medical professionals, hospitalization in past year, 
current smoking, alcohol intake (>one drink a week).   
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Table 8. Multivariate analysis: variables significantly associated with CAM use. 
Variable OR* 95% C.I. P value 
    
Presence of psychiatric disorders   0.019 
   None 1.00   
   Dementia only 0.95 0.45-1.98 0.88 
   Depression (case level) only 2.27 1.03-5.00 0.04 
   Depression (include subsyndromal case) only 2.06 1.31-3.25 0.002 
   Depression co-morbid with other disorders   1.11 0.59-2.09 0.74 
   Any psychiatric disorders 1.52 1.06-2.18 0.022 
    
Self-rated mental health   0.017 
   Poor / Fair 2.40 1.23-4.71 0.011 
   Good/very good 2.10 1.24-3.54 0.0058 
   Excellent 1.00   
    
Age    0.0006 
  60~69 1.00   
  70~79 0.86 0.64-1.15 0.32 
  80~ 2.04 1.34-3.10 0.001 
    
Ethnicity    0.0001 
  Chinese   3.53 2.10-5.95 0.0001 
  Malay 1.71 0.90-3.27 0.106 
  Indian 1.00   
    
Regularly visit a health care provider 1.56 1.19-2.05 0.002 
    
See the same GP   0.0009 
  Almost never 1.96 1.09-3.52 0.025 
  Some of the time 2.13 1.35-3.37 0.001 
  Most of the time /always 1.00   
    
Social activity levels   0.0001 
  Low (0~2) 1.00   
  Intermediate (3~5) 1.81 1.37-2.40 0.0001 
  High (≥6) 2.70 1.72-4.21 0.0001 
    
Prescription drugs do more harm than good   0.002 
   No (Strongly disagree/disagree) 1.77 1.28-2.45 0.0006 
   Neutral (Neither agree nor disagree) 1.00   
   Yes (Agree/strongly agree) 1.17 0.70-1.96 0.54 
    
 
* Weighted estimates of odds ratio and 95% confidence intervals 
Variables entered in multivariate model: 
age, gender, ethnicity, marital status, income, financial inability, psychiatric disorders, self-rated mental health, 
comorbidities, functional status, distrust of prescribed medicine, doctor visits, see the same GP, social activities score, 








* MHPs include psychiatrist, psychologist, psychiatric nurse and mental health counsellor 





Table 9. Health beliefs, attitudes and behaviors of CAM users and non-users among 131 respondents with 
depression 




2 df P 
   N  Weighted % N  Weighted %    
                
Sought help from GP 7 12.8 7 8.0 0.70 1 0.40 
        
Sought help from mental MHP * 1 2.4 3 7.8 NC   NC NC 
        
Sought help from MHP or GP 7 12.8 9 15.1 0.13 1 0.72 
        
Sought help from traditional medicine practitioner 1 2.4 0 0.0 NC   NC NC 
        
Treated with psychotropic medications 5 10.0 5 9.2 0.02 1 0.89 
        
I can overcome my problem without professional help     0.84 2 0.65 
   Strong disagree/disagree 33 51.7 43 55.5    
   Neither disagree nor agree 9 19.4 13 13.1    
   Agree/strong agree 17 28.9 16 31.5    
        
Spiritual help is source of support     0.76 2 0.68 
   Not at all 6 12.3 4 11.5    
   To some extent 26 50.0 27 43.0    
   To a great extent 27 37.7 41 45.5    
        
Family able to help me      0.06 2 0.97 
   Not at all 10 14.4 13 15.2    
   To some extent 21 36.2 22 34.0    
   To a great extent 28 49.4 37 50.8    
        
Financial limitation for needed medical service     3.20 2 0.20 
   Not at all 22 40.7 14 25.0    
   To some extent 22 38.9 33 47.9    
   To a great extent 15 20.5 25 27.1    
        
Embarrassed about mental illness     9.10 1 0.0026 
   Not at all 42 76.8 36 50.5    
   To some /great extent 17 23.2 36 49.5    
        
Believe mental illness can be cured     0.55 2 0.76 
   Not at all 6 12.3 7 8.2    
   To some extent 43 69.6 54 72.2    
   To a great extent 10 18.1 11 19.6    
        
MHPs can do little to help     4.94 2 0.08 
   Strong disagree/disagree 41 74.4 38 57.7    
   Neither disagree nor agree 14 21.6 28 29.4    
   Agree/strong agree 4 4.0 6 12.9    
        
Prescription drugs do more harm than good     0.12 2 0.94 
   Strong disagree/disagree 46 77.0 46 74.8    
   Neither disagree nor agree 6 14.1 14 16.5    
   Agree/strong agree 7 8.9 12 8.8    
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4.4 Study IV: Drug use and depressive symptoms 
The overall prevalence of depressive symptoms in our sample (N=2804) was 13.1%. 
Depressed participants were older, less educated, more often lived in smaller low-end 
apartments and had lower social support compared with non-depressed participants. They 
were more likely to rate their health as fair or poor and had a higher number of medical 
conditions (Table 10). They also reported higher rates of cognitive impairment, IADL 
disability, ADL disability and government medical facility use than did non-depressed 
participants. There were no differences between depressed and non-depressed 
participants with regard to gender, ethnicity, frequency of regularly seeing the same 
doctor, total cholesterol level and BMI. 
 
Table 11 presents the results of bivariate analysis between depressive symptoms and drug 
use, categorized in 11 different classes. The use of ACE-inhibitors was positively 
associated with depressive symptoms, while the use of β-blockers, calcium antagonists, 
diuretics were not significantly associated with depressive symptoms. Other drug classes 
that had a significant bivariate association with depressive symptoms included: 
antiparkinsonism, systemic corticosteroids, H2- blockers, tranquilizers, hypnotic and 
sedatives (all p<0.05). Statins and NSAIDs showed no apparent associations with 
depressive symptoms in bivariate analysis. 
  
Multivariate analysis that controlled for the confounding effects of risk factors and 
correlates of depression revealed significant associations at 5% level with depressive 




Statins use was inversely associated with depressive symptoms (OR, 0.71; 95% C.I., 
0.52-0.97) in the whole sample (non-significant age interaction).  
 
Corticosteroids use was also associated with depressive symptoms (OR, 2.44; 95% C.I., 
0.92-6.49) in the whole sample, although with marginal significance. In participants 
younger than 65, no apparent association was observed, but in participants aged 65 and 
over, systemic corticosteroids was significantly associated with depressive symptoms 
(OR, 4.02; 95% C.I., 1.12-14.4); p value of age interaction term was 0.18. 
 
H2-blockers use was positively associated with depressive symptoms (OR, 1.47; 95% C.I., 
1.01-2.52) in the whole sample. Both the main effect of H2-blockers and the interaction 
term between H2-blockers and age were significant (p=0.01) in the multivariate model. In 
age-stratified analysis, the association between H2-blockers and depressive symptoms 
was found in participants aged less than 65, the adjusted OR was 4.67 (CI 1.59 to 13.74), 
but no association was found in older persons over 65 years.  
 
Although antiparkinsonism and tranquilizers/hypnotic/sedatives were associated with 
depressive symptoms in bivariate analysis, their associations disappeared controlling for 
other covariates. Likewise, no main effect and age interaction of other drug classes with 
depressive symptoms were observed. 
  
We conducted further analysis with cholesterol level and BMI. Both variables were not 
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found to be associated with depressive symptoms and did not alter the results of ORs of 
associations of depressive symptoms with the drugs reported above.  
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Table 10. Respondent characteristics by depressive symptoms status (N=2804) 
 Depressive symptoms 
(N=368) 
 No depressive symptoms  
(N=2436) 
P value 
 N %  N %  
Age       0.01 
  55-60 90 24.5  569 23.4  
  60-65 84 22.8  575 23.6  
  65-70 71 19.3  585 24.0  
  70-75 48 13.0  370 15.2  
  75-80 42 11.4  210 8.6  
  80-85 18 4.9  79 3.2  
 85 + 15 4.1  48 2.0  
Gender(female) 237 64.4  1534 63.0 0.60 
Ethnicity      0.34 
  Chinese 347 94.3  2264 92.9  
  Malay and Indian 21 5.7  172 7.1  
Housing type      <0.001 
  1-3 rooms public housing  156 42.4  684 28.1  
  4-5 rooms public housing 120 32.6  966 39.7  
  Other higher end housing 92 25.0  786 32.3  
Educational status      <0.001 
  No education 79 21.5  459 18.8  
  Primary/secondary or ITE 254 69.0  1565 64.2  
  Pre-u or poly/University 35 9.5  412 16.9  
Social-emotional support score 
lowest tertile 
     <0.001 
   Lowest tertile(≤49) 175 47.6  661 27.1  
   Intermediate tertile(49~53) 120 32.6  841 34.5  
   Highest tertile(>53) 73 19.8  934 38.3  
Self-rated physical health      <0.001 
  fair or poor 51 13.9  79 3.2  
  good 211 57.3  838 34.4  
  Very Good or excellent 106 28.8  1519 62.4  
Number of medical conditions      <0.001 
0~1 122 33.2  1089 44.7  
   2 98 26.6  594 24.4  
  >2 148 40.2  753 30.9  
Cognitive impairment 79 21.5  281 11.5 <0.001 
IADL disability  133 36.1  499 20.5 <0.001 
ADL disability 50 13.6  131 5.4 <0.001 
       
Type of medical facility use      <0.001 
  Private 102 27.7  942 38.7  
  government 266 72.3  1494 61.3  
Regularly see the same doctor      0.21 
  Never 31 8.4  190 7.8  
  Some of the time 70 19.0  443 18.2  
  Most of the time 93 25.3  748 30.7  
  All the time 174 47.3  1055 43.3  
Total cholesterol      0.36 
  ≤4.8 108 29.4  622 25.5  
  4.9~5.4 85 23.1  577 23.7 
 
 
  5.5~6.0 98 26.6  650 26.7  
  ≥6.1 77 20.9  587 24.1  















95%CI  P value 
 N %  N %      
           
Antihypertensives           
ACE-inhibitors 41 11.1  182 7.5  1.55  1.09-2.22  0.02 
 β-blocker 77 20.9  525 21.6  0.96  0.74-1.26  0.78 
Calcium antagonists 59 16.0  361 14.8  1.10  0.81-1.48  0.54 
Diuretics 29 7.9  169 6.9  1.15  0.76-1.73  0.51 
Antiparkinsonism 9 2.5  13 0.5  4.67 1.98-11.01  0.001 
H2 blockers 23 6.3  92 3.8  1.70  1.06-2.72  0.03 
Statins 84 22.8  585 24.0  0.94  0.72-1.21  0.62 
NSAIDs 10 2.7  67 2.8  0.99  0.50-1.94  0.97 
Systemic corticosteroids 7 1.9  16 0.7  2.93  1.20-7.18  0.02 
Tranquilizers,hypnotic  
and sedatives 
11 3.0  32 1.3  2.32  1.16-4.63  0.01 
Use of other drugs 204 55.4  1057 43.4  1.62  1.30-2.02  0.0001 




















Table 12. Multivariable analysis of associations between drug class and depression symptoms by age groups (N=2804)  
Drug class 
Whole Sample  Age<65  Age≥65 
OR 95% CI  OR 95% CI  OR  95%CI 
         
Antihypertensives         
ACE-inhibitors 1.11 0.73-1.68  0.47 0.20-1.13  1.56 0.95-2.57 
β-blocker 0.90 0.66-1.21  0.75 0.47-1.20  1.01 0.67-1.52 
Calcium antagonists 0.91 0.65-1.29  0.76 0.41-1.44  1.07 0.70-1.63 
Diuretics 1.07 0.68-1.67  1.51 0.69-3.32  0.92 0.53-1.62 
Antiparkinsonism 1.66 0.60-4.63  0.59 0.07-5.26  2.33 0.71-7.67 
H2- blockers 1.47 1.01-2.52  4.67 1.59-13.74  0.93 0.48-1.82 
Statins 0.71 0.52-0.97  0.76 0.46-1.24  0.66 0.43-1.00 
NSAIDs 0.67 0.32-1.41  0.34 0.09-1.23  1.12 0.44-2.83 
Systemic corticosteroids 2.44 0.92-6.49  0.95 0.16-5.78  4.02 1.12-14.42 
Tranquilizers/hypnotic/sedatives 1.29 0.54-3.09  1.32 0.33-5.30  1.44 0.45-4.56 
Use of other drugs 1.12 0.85-1.48  1.03 0.69-1.53  1.26 0.84-1.88 
         
 
Depressive symptoms was the outcome variable in this multivariate model, all the drug class variables were forced into the same 
model. OR of association with depressive symptoms were adjusted for age, educational status, housing type, social-emotional 
support, number of medical conditions, functional disability, cognitive impairment, self-rated physical health and type of medical 
facility;   










5.1 Study I: Psychiatric disorders and acute hospitalization risk 
Our finding of an association of psychiatric disorders with hospitalization risk is in 
agreement with those reported in two previous studies .
26,84
 In one study of 
community-living elderly ,
84
 depression was identified from one question, while in 
another study, Huang et al 
26
 measured depressive symptoms using CES-D scale. Our 
present study involved community-living elderly and used a clinical diagnostic definition 
of psychiatric morbidity, and demonstrated that psychiatric disorders was associated with 
hospitalization risk independently of socio-demographic factors, physical health status 
and health seeking behaviors.  
 
We also identified other significant risk factors for increased risk of hospitalization which 









As a limitation of the study, the cross-sectional data used in this analysis does not permit 
us to establish the directionality of the association between psychiatric morbidity and 
acute hospitalization risk. It is conceivable that psychiatric disorders may increase the 
risk of hospitalization for various medical disorders; on the other hand, acute 
hospitalization episode(s) for these disorders may result in subsequently more episodes of 
psychiatric morbidity. Both are possible, and in the context of healthcare provision, the 
distinction may be academic. In any case, the finding underlines the importance of 
treating psychiatric morbidity in primary care to avoid excessive and unnecessary acute 
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hospitalization, as well as to treat psychiatric morbidity during or after a hospitalization 
episode.  
 
The mediating factors between psychiatric morbidity and increased hospitalization risk 
are multiple and complex, and likely to be embedded in a multi-directional web of 
inter-relationships with physical illnesses and functional health status, socio-economic 
status and health care utilization. Elderly patients with chronic medical conditions may 
more easily become depressed because of long term illness, and depression may worsen 
their medical disorders,
258
 partly because of treatment non-adherence. A continual cycle 
of depression and treatment non-adherence may result in a downward spiral of acute 
exacerbations and complications and poor health and functional status,
259
 resulting in 
more visits to a primary care provider prior to eventual hospitalization. 
Post-hospitalization onset of depressive or psychotic disorders is also possible, as 
exemplified by post-stroke depression. Further studies should address these possible 
mediating relationships.  
  
We also observed that neither a case level diagnosis of dementia nor cognitive 
impairment measured by MMSE was associated with increased hospital use. This finding 
is in agreement with previous research findings,
90,252,255,260
 but other studies have reported 
positive associations for community-living elderly .
254,261,262
 Among nursing home 
residents, negative associations
263,264
 have been reported. The inconsistent results may be 
explained by differences in selection characteristics of study populations and 
confounding by medical comorbidities and health status. Nursing homes may provide 
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more ready access to care, thereby reducing the need for hospitalization; or may also 
recognize the limited benefit of hospitalization for demented residents, thus providing 
acute care for these residents without transfer.  
 
However, co-morbid psychiatric disorders (depression, dementia and others) were 
significantly associated with higher risk of hospitalization. It could be argued that 
depression may interact with dementia and other psychiatric disorders. Hence, co-morbid 
psychiatric disorders could worsen functional performance and chronic diseases such as 
COPD and heart failure, therefore, resulting in increased risk of hospitalization.  
 
In conclusion, our study demonstrated that in the elderly, psychiatric morbidity was 
significantly associated with increased hospitalization risk, independently of other risk 
factors such as socio-economic status, medical co-morbidities, poor physical health status, 
and healthcare use. The complex relationships between psychiatric morbidity and medical 
and psychosocial factors and hospitalization in the elderly require further studies.        
 
5.2 Study II: Depressive symptoms and health service use (hospitalization and doctor 
visits 
In this study, we investigated the two-way associations between depressive symptoms 
and health service use measures of hospitalization and doctor visits over a one year 
period. The principal observations were that the presence of depressive symptoms at 
baseline was associated with subsequently increased doctor visits (RR=1.34, 95% CI, 
1.05-1.70), but not with subsequent hospitalizations. On the other hand, both 
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hospitalization (RR=6.43, 95% CI,2.48-16.65) and doctor visits (RR=5.89, 95% 
CI,2.26-15.36) measures of health services use for chronic medical illnesses during the 
one year study period were associated with subsequent development of depressive 
symptoms at 1 year. 
   
Our observation of a positive association between baseline depressive symptoms and 
subsequently increased doctor visits independent of medical comorbidity and other 




 have suggested 
that the link between depressive symptoms and increased episodes of physician 
consultation could be due to the tendency of depressed patients to amplify medical 
symptoms, the worsening of medical conditions by direct biological mechanisms such as 
alteration in cellular immunity and platelet activity
267,268
 or by indirect behavioral factors 
such as non-adherence to medical treatment and poor self-care among depressed 
patients,
259
 and other unrecognized underlying diseases. Other authors have reported that 
depressed patients always had distorted views of their susceptibility to and the severity of 
their medical illnesses,
269
 and that this factor rather than the desire to use health services 
was the primary determinant of higher consultation rates.   
   
Consistent with other findings from population-based studies, 
87-89,100,101 
we found that 
depression at baseline was not associated with subsequently increased hospitalization 
risks. However, a minority of studies have reported a positive association in older 
subgroups of community-living elderly population 
26,84
 or among older patients with 
chronic medical conditions. 
60,95,96
It is possible that in depressed persons, decreased 
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emotional responsiveness and diminished drive and motivation may impair 
decision-making and raise threshold for help-seeking.
105,270
 By delaying or postponing 
seeking inpatient hospital care, depressed elderly under-report their actual health service 
use experiences. This may result in under-estimation of the number of hospitalizations 
over the short-term, but longer term follow-up may uncover the association. It is also 
possible that the actual impact of mental disorders on health service use may be easily 
masked by the extant high level of health service use in the elderly. Depressive symptoms 
likely play a predisposing role secondary to the direct roles of physical illnesses factors in 
increasing acute hospitalization use. In community-based studies of the elderly, milder 
subsyndromal depression may not be as strong a predictor of acute hospitalization use as 
clinical grade depression in hospital-based studies of older elderly with severe chronic 
diseases.  
 
Our findings suggest that increased doctor visit and hospitalizations for chronic medical 
illnesses were associated with subsequent greater likelihood of developing depressive 
symptoms. This is most likely related to the fact that the frustration of dealing with 
chronic health problems that are not improving despite multiple visits to doctors and 
disruptive, expensive short hospital stays may overwhelm some patients‟ capacity to cope, 
cause despair, and thus result in reactive depression. Multiple drug therapy that 
accompanies increased physician consultations and hospitalization is another possible 
factor contributing to the increased risk of depression in the elderly with chronic physical 
comorbidities. A large number of drugs including antihypertensives (ACE-inhibitors, 
β-blockers, calcium antagonists), diuretics, antiparkinsonism drugs, H2-blockers, NSAIDs, 
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systemic corticosteroids, tranquilizers, hypnotic and sedatives are reported to be capable 
of causing depression in elderly patients.  
  
Since effective biological and psychological treatments exist for most forms of 
depression, the findings in our study point to the possibility that providing depression 
treatment may reduce unnecessary excess of health service use by depressed older 
patients. Unfortunately, depressive symptoms are generally under-recognized and 
undertreated in the elderly. Research has shown low rates of diagnosis of depression in 
elderly patients in primary care settings.
271
Fewer than half of primary care patients with 
depression are actually treated.
272,273
 There are many contributing factors. First, older 
adults may have stigmatizing beliefs associated with depression or may consider 
depression as a „natural‟ reaction to difficult life circumstances, and therefore, not seek 
help.
274,275
 Medical comorbidity often complicates the diagnosis and treatment of 
depression, and doctors may be less likely to recognize depression in older patients who 
present with somato-dysphoric symptoms, and may not think that psychiatric treatment is 
necessary or effective.
276
 Our study shows that a better understanding and awareness of 
the complex relationship between depression and healthcare use will help to improve 
recognition and treatment of depression in elderly patients with large numbers of 
consultation episodes and hospitalization.    
 
The strength of the present research is that a longitudinal study design was used to follow 
up a community-living cohort of seniors; because they were collected at close intervals, 
data on the frequencies of doctor visits and hospitalization episodes were more accurate 
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and complete by minimizing recall difficulties and bias.  
 
Still, there are limitations, and the results should be interpreted with some care. First, by 
using the GDS to determine depressive symptoms, the study did not elicit the presence of 
clinical grade depression with the use of a more stringent diagnostic interview instrument. 
It was possible that the study lacked the ability to demonstrate the more pronounced 
effect of clinical depression on hospitalization. Nevertheless, by using the GDS to 
identify predominantly cases of subsyndromal grades of depression, the results 
demonstrated that milder cases of depression typically seen in primary care did have 
tangible impact on healthcare use. Secondly, limitations in sample size and the short 
follow up period may preclude us from observing a delayed more pronounced effect of 
depression on hospitalization risk, and the limited monitoring frequencies of depressive 
symptoms do not allow us to clearly establish the cause-effect relationship between 
depressive symptoms and health service use. Finally, it is possible that some unmeasured 
or unknown important variables such as severity of illnesses, chronic pain, health belief 
and caregiver and physician characteristics may produce residual confounding in the 
observed relationships.    
 
In conclusion, we found that depressive symptoms and healthcare use in older adults had 
positive relationships. While the presence of depressive symptoms may predispose to 
increased episodes of healthcare use, especially physician visits, it is also clearly an 
aftermath resulting from increased healthcare use for worsening medical comorbidity. 
Primary care physicians should attach importance to recognizing and treating depression 
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in elderly patients after hospital discharges for medical diagnoses. 
 
5.3 Study III: Depression and self-rated mental health with CAM use 
We found in this study that compared to nonusers, CAM users were more likely to rate 
themselves to be in poor mental health (OR=2.40, 95% CI,1.23-4.71) or have a probable 
mental disorder.(OR=1.52,95% CI,1.06-2.18) This confirms previous studies using 
self-reports of depression, depressive symptom scales and other surrogates such as 
psychotropic medication use 
4,6,127
 which have reported an association of depression with 
CAM use in elderly populations. Only one previous study has used structured diagnostic 
interview instruments to diagnose mental disorders,
28
 and this is a strength of the present 
study. We also controlled for potential confounding by a wide range of other correlates of 
CAM use such as age, gender, ethnicities, medical comorbidities, leisure activity, 
frequency of doctor visits, which have also been shown in the present and previous 
studies to have robust associations with CAM use.  
 
Among CAM users, the proportion of those with a diagnosis of probable mental disorder 
was high (22% compared to 16% in non-users, Table 7). This is similar to the proportion 
of 21% reported in the study by Unutzter 
28
among adult users of CAM in the US. The 
fact that considerable numbers of CAM users do have mental problems has important 
implications for primary care providers and mental health specialists who should 
therefore be aware of the association of mental illnesses with CAM.  
 
Among respondents with the most common mental disorder, depression, it was not 
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surprising to note that in this Asian population, only 14% reported receiving conventional 
treatment by a health professional. It has been widely reported in many studies that 
mental disorders are highly prevalent but often go untreated. Our low proportion of 
treated cases is typical of the proportion (typically less than a quarter) found in 
developing and Asian countries and among Chinese populations in mainland China and 
Hong Kong.
277-279
 It is therefore interesting to note that a considerably greater proportion 
(60%) of those with depression reported using CAM, mostly traditional herbal medicines 
instead.  
 
Studies in Western populations investigating CAM use in the general adult populations 
reflect prevailing concerns over growing numbers of patients turning to CAM, possibly 
because of dissatisfaction with conventional mental health services. In Asian populations, 
CAM use has always been common in older adults, reflecting a long-standing cultural 
tradition of health care behavior that seeks help from traditional Chinese herbalists 




We could find no evidence in this study to indicate that CAM users among individuals 
with depression were less likely to seek treatment from general and mental health 
professional trained in Western medicine or were more likely to have negative beliefs and 
attitudes about mental illnesses and their treatments. This is consistent with the common 
observation from different authors that the use of CAM complements rather than replaces 




In many Asian countries including China (mainland China, Hong Kong) and Singapore, a 
dual parallel system of traditional Chinese medicine and modern Western medicine has 
long been established. In this system, practitioners trained in Western medicine rarely 
prescribe Chinese herbal medicines for mental disorders. CAM in respondents with 
mental disorders were thus prescribed by traditional Chinese herbalists or self-prescribed 
for diagnosis of „neurasthenia‟ („shen jing shuai ruo‟). „Neurasthenia‟ is an accepted 
non-stigmatizing diagnostic label that is generically applied to a wide-range of depressive, 
somatic and cognitive symptoms.
283
 Studies of Chinese patients with depression have 
shown that they typically initiate somatic distress that was related to affective and 
cognitive psychopathology .
284
 This somatopsychic mode of reporting psychological 
distress is probably the salient cues to use traditional herbal medicines. 
 
A limitation of our study is that respondents‟ recall of CAM use over a 12-month period 
may result in some underreporting of CAM use. We did not ask the respondents directly 
whether they had used CAM to treat their symptoms of mental distress or mental disorder. 
Detailed information was lacking for the specific Chinese herbal medicines that 
respondents used, but we did ask for detailed information on all Western prescription 
medications and other over-the-counter health products, and found that none of the 
respondents had used St. John‟s wort (hypericum).  The relationship between the 
respondents‟ use of traditional herbal medicines and specific symptoms of mental distress 
or neurasthenia was not examined in detail in this study, and should be further explored in 




To sum up, in this community-based sample of Asian Singaporean older adults, poor 
self-reported mental health and depression were associated with CAM use, independent 
of other correlates of CAM use. Depressed Asian older adults were much more likely to 
use traditional Chinese herbal medicines than to seek conventional health care providers. 
However, this was not related to negative beliefs or attitudes about Western-style 
medicines or conventional health care providers. 
 
 
5.4 Study IV: Drug use and depressive symptoms 
The present study provides data that empirically support a positive association with 
depressive symptoms for two drug classes (H2-blockers and corticosteroids) among many 
that are purported from contemporary reference sources to be capable of causing 
depression. The lists of such drugs in psychiatric and pharmacological literature are 
inconsistent and discordant, and strong evidence supporting the existence of causal 
associations is often lacking. At best, for a number of drugs, the evidence is suggestive, 
although not conclusively, of a causal association .
40,41 
 
Interestingly, we found an inverse association between statins use and depressive 
symptoms that was independent of cholesterol level and BMI. Recent clinical studies of 
statins have reported a lack of association with depression or other mood 
disturbances;
204,205
 conversely, some studies have reported an apparent protective effect 
of statins use on depression.
207,209
 Our finding thus corroborates the results of studies 
suggesting that reported stains use did not lead to an increase in depressive symptoms and 
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indeed may decrease depressive symptoms.  
 
Studies have shown that cardiovascular diseases are associated with an increase in 
depressive symptoms.
285,286
 It is thus possible that statins could lower the risk of 
depression through its lipid-lowering and long-term effects in reducing the incidence of 
cardiovascular diseases.
287,288
 Nevertheless, we found this inverse association between 
statins and depressive symptoms to be true in further analysis of respondents who were 
free of cardiovascular diseases and stroke, suggesting that the association may not just be 
attributable to the presence of cardiovascular diseases.  
 
The evidence also suggests that patients might be vulnerable to depression during the first 
month of lipid-lowering therapy, but not with long-term use over more than a year.
210
 The 
underlying mechanism is purported to be the time limited change in serotonin transporter 
activity, which has been reported to increase in the first few months of lipid-lowering 
therapy before starting to decrease and finally return to the pre-treatment level at one year. 
In this study, all the participants had used statins for at least 3 months prior to the baseline 
interview and we found a null association between cholesterol level and depressive 
symptoms. It is also postulated that statins have an antidepressant effect by improving 
cerebral perfusion and oxygenation.
289
 However , it is also possible that depressive 
symptoms could possibly be reduced among patients with better health perception and 




We observed that the use of H2-blockers was positively associated with depressive 
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symptoms, and among the adults younger than 65 years. Previous studies have reported 
mixed findings of the association between H2-blockers use and depressive 
symptoms
35,229,230,235,291
 In the virtual absence of any biologically plausible mechanism to 
explain this, it is likely that the illnesses for which H2-blockers were prescribed were 
partially or wholly responsible for the observed elevation in depressive symptoms, since 
depression has been reported to be positively associated with dyspeptic and irritable 
bowel syndromes,
293
 and furthermore H2-blockers are readily available over the counter 
without doctors‟ prescription in Singapore. This was demonstrated by the strong 
association between self-reported gastro-intestinal disorder and depressive symptoms in 
an earlier study.
293
 It is also not clear why the association between H2-blockers and 
depressive symptoms was found only in younger elderly; our data suggest that 
gastro-intestinal problems were more prevalent in old-old than in young-old. Further 
research is needed to confirm our findings.  
 
Our study suggests that systemic corticosteroids use was associated with increased 
depressive symptoms in older elderly over 65 years, although the statistical power was 
limited by the small number of corticosteroids users (N=23). This agrees with the positive 
association reported in previous studies.
38,221
  There is ample evidence to suggest that 
the reverse causation (depressive symptoms causing corticosteroid use) seems unlikely 
and that the association is biologically plausible.
214,226,227
 Age-related changes in 
pharmacokinetics and pharmacodynamics may increase the likelihood of depressive 
symptoms among the older people aged ≥65. Elderly on corticosteroids may be at higher 
risk of depression due to increased total exposure to glucocorticoids as elderly have 
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blunted and delayed inhibition of ACTH to exogenous cortisol.
228 
It is also likely that the 
link between depressive symptoms and chronic illnesses such as arthritis and asthma may 
explain the observed association as about 60% patients used steroids for these conditions 
in our sample. 
 
We could find no strong evidence in support of positive associations with depressive 
symptoms for other drugs that included antihypertensives, antiparkinsonism, NSAIDs, 
and tranquilizers/hypnotic/sedatives, which have been implicated in causing depression at 
times. These drugs were shown in the present study to be associated with depressive 
symptoms in crude analyses, but their associations disappeared after controlling for 
confounding variables. For example, previous studies have reported a positive association 
of ACE inhibitors with depression.
178,184
 Our results suggest that previous studies may 
have inadequately controlled for confounding variables. Although our bivariate analysis 
showed that ACE inhibitors use was indeed significantly associated with depressive 
symptoms (OR=1.55, p=0.02), the OR after adjusting for multiple confounding variables 
was substantially reduced towards the null value of association. Nevertheless, it was also 
interesting to note a positive association (OR=1.56, 95% C.I. 0.95 – 2.57) in those aged 





The strengths of the present study include the use of highly valid and reliable scale to 
assess depression, a population-based cohort of unselected drug users, and large sample 
size that allowed for subgroup analysis. 
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The study has limitations. The presence of depressive symptoms as determined by the 
GDS is not tantamount to a diagnosis of depressive disorder, which would be preferable 
in making the associations more specific for clinically relevant depression. Somatic 
symptoms common in the elderly may be a source of confounding and bias if they are a 
source of item response bias in depression scales. However, the GDS was specially 
chosen because it was remarkably free of item response bias due to somatic symptoms. 
This was firmly supported in our analysis of differential item functioning of the GDS in 
Singaporean elderly.
294
 The confounding influence of chronic physical illnesses was also 
controlled for in the multivariate analyses. As with most cross-sectional study designs, 
the strength of association may be over-estimated by the OR. A number of statistically 
significant associations may also be spurious given the multiple comparisons. On the 
other hand, the study is also greatly limited in its power to detect any but a few 
exceptionally strong associations for other reasons. If an association was present, it could 
be masked by dose reduction, discontinuing medication or initiating a treatment of 
depressive symptoms among the population. Additionally, it is difficult to prevent the 
results from being biased by prescriber expectancy, drug channeling, and confounding by 
contra-indication.
295
 As illustrated in the observed association between H2- blockers use 
and depressive symptoms, it is difficult to determine the temporal cause-and-effect 
relationship between drug use and depressive symptoms. Other study limitations include 
the lack of information on drug dosage, medication adherence and duration and severity 




Clinicians often have to review medications when drug-induced depression is suspected, 
and make decisions about whether to stop or discontinue them. Although 
“Substance-induced mood disorder” is a distinct diagnostic category in the Diagnostic 
and Statistical Manual of Mental Disorders IV (DSM-IV),
296 
it is usually difficult to make 
judgments about drug etiology, and this is not helped by the sparse evidence available in 
the research literature. Despite the limitations of study design, our findings add to the 
evidence that use of certain classes of medication is associated with depression, and 
provide a firmer evidence base for clinicians to evaluate suspected drug-induced 
depression.  
 
In conclusion, we found evidence in support of an inverse association of the use of statins 
with depressive symptoms. Corticosteroids use was also evidently associated with 
depressive symptoms in older persons over 65 years; H2-blockers use was also observed 
to be associated with increase in depressive symptoms in patients aged<65 years but this 




CHAPTER 6 SUMMARY AND CONCLUSION 
Our findings add to the growing evidence linking depression to more healthcare use in 
the elderly.  
 
In Study I, we found that the presence of comorbid psychiatric disorders was positively 
associated with hospital use, in agreement with other published findings. However, in 
common with other studies, we did not find that depression was prospectively related 
with hospitalization risk in Study II. Nevertheless, we found depression was associated 
with subsequent doctor visits. In this study, we also noted that older people with more 
health service use were at increased subsequent risk of being depressed.  
 
In Study III, we found that depression was shown to be associated with CAM use. 
However, CAM use by depressed patients did not appear to be related to negative beliefs 
on conventional medicines and health providers. Higher CAM use in Asian older adults 
with mental disorders could be attributed to a long cultural tradition of using traditional 
medicines as complement instead of alternative to conventional treatment. Further studies 
to explore the association between the use of specific herbal medicines and depressive 
symptoms may help to clarify the relationships between mental disorders and CAM use.  
 
In Study IV, use of some drug classes was demonstrated to be related to depression. Our 
results add to a body of good evidence that corticosteroids use may cause depression. In 
addition, this was more likely to be observed in older elderly persons. We found 
H2-blockers was positively associated with depression, especially in younger elderly aged 
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under 65. However, it was possibly due to underlying gastrointestinal disorders for which 
H2-blockers were prescribed. Our results also add to a growing body of evidence that the 
use of statins may possibly reduce depression through non-cholesterol mechanisms, but 
this should be confirmed by rigorous randomized controlled studies. Conversely, other 
drug classes such as antihypertensives were not associated with depression. 
 
Our findings underscore the importance of recognizing and treating depressive symptoms 
and depression in the elderly with chronic illnesses. Healthcare interventions that address 
depressive symptoms and disorders in elderly patients with chronic medical disorders 
may contribute to decreasing the high cost of healthcare in the older population. 
 
In future, well-controlled cohort studies or clinical trials with large sample size should 
examine whether specific interventions targeting at depression can decrease health 
service use and confirm cause-effect relationships between drug use and depressive 
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